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Abstract: Radiation therapy (RT) is frequently used as part of the standard of care treatment of
the majority of brain tumors. The efficacy of RT is limited by radioresistance and by normal tissue
radiation tolerance. This is highlighted in pediatric brain tumors where the use of radiation is limited
by the excessive toxicity to the developing brain. For these reasons, radiosensitization of tumor
cells would be beneficial. In this review, we focus on radioresistance mechanisms intrinsic to tumor
cells. We also evaluate existing approaches to induce radiosensitization and explore future avenues
of investigation.
Keywords: radiation therapy; radioresistance; brain tumors
1. Introduction
1.1. Radiotherapy and Radioresistance of Brain Tumors
Radiation therapy is a mainstay in the treatment of the majority of primary tumors of the
central nervous system (CNS). However, the efficacy of this therapeutic approach is significantly
limited by resistance to tumor cell killing after exposure to ionizing radiation. This phenomenon,
termed radioresistance, can be mediated by factors intrinsic to the cell or by the microenvironment.
One approach to overcome radioresistance has been to alter the parameters under which radiotherapy
is delivered and another has centered on understanding the molecular complexity that underlies
radioresistance with the aim of developing targeted therapies. This review summarizes these efforts in
the context of primary brain tumors.
1.2. Effects of Radiation on Normal Brain Tissue
The inherent radiosensitivity of normal brain tissue manifests as late toxicity in the form of
radionecrosis and is evident in some patients after completing CNS-directed radiotherapy. This is not
to be confused with the term “pseudoprogression” which describes a radiological finding thought
to represent radiation damage to the tumor itself rather than normal brain toxicity [1]. In contrast
to pseudoprogression, radionecrosis does not resolve spontaneously and is often associated with
outward clinical findings, such as recurrent seizure and focal neurological symptoms. On histological
review, gliosis, apoptotic endothelial cell death and white and gray matter necrosis are evident.
Additionally, there are T2-signal abnormalities, indicating increased vascular permeability that
lead to white matter edema that is visible on MRI [2,3]. One of the key mechanisms thought to
contribute to radionecrosis is radiation-triggered endothelial cell and oligodendrocyte demise primarily
through apoptosis. This leads to demyelination and microenvironmental dysfunction through chronic
hypoxia and inefficient vascular remodeling. This process contributes to the perpetuation of chronic
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inflammatory mediators such as tumor necrosis factor-α and increased transactivation by NF-κB [2,4–7].
Post-irradiation vascular insufficiency leads to chronic ischemia, which contributes to worsening
hypoxia, nutrient deficiency, increased oxidative stress and reactive oxygen species (ROS) generation,
toxic to normal brain parenchyma in the vicinity. As reactive oxygen species are central to damage
caused by radiation [8], antioxidants have been investigated for their potential protective effect of
normal cells in the context of other malignancies. However, results of clinical trials using antioxidants
have been disappointing and new opportunities are being evaluated, such as agents affecting pathways
leading to bystander genome destabilization [9].
2. Dose Escalation and Altered Fractionation to Combat Radioresistance
Modulation of radiation’s delivery is an approach that can be readily pursued through alteration
of total cumulative dose delivered or adjustment of the fractionation schedule in order to exploit
differences between the radiobiology of the tumor and normal tissues. Data-driven incremental
dose escalation has improved local control for many different tumor types, including prostate and
lung carcinomas [10–15], but dose escalation for primary brain tumors has been an exercise in
futility [16]. Technical advances in radiation delivery [intensity modulated radiation therapy (IMRT)
and protons] that limit the dose to peritumoral brain has permitted hope to exist that this approach
may still have merit [17]. Mathematical modeling and simulation of glioblastoma radiobiology
have identified ostensibly more efficacious radiation fractionation schedules compared to standard
fractionation [18–21]. However, clinical trials evaluating non-standard radiotherapy fractionation
schedules for glioblastoma have not shown promise [22–26].
Computerized approaches to image registration, both at the time of radiotherapy planning and
at the time of radiation delivery, have permitted more accurate target volume definition and more
accurate treatment delivery [27,28]. Because in the CNS there are specialized structures with more
limited radiation tolerance [29–33], these technical advances have allowed for smaller planning target
volume margins to cause less normal tissue dose exposure [34–37]. Computerized control of radiation
delivery using approaches, such as IMRT and volumetric modulated arc therapy, have permitted
increasingly complex treatments that reduce the dose absorbed to these critical normal tissues, while
delivering a tumoricidal dose to the target in acceptably brief treatment appointments [38–41].
In recent years, stereotactic radiosurgery (SRS) has been evolving to safely deliver ablative high
doses of focused radiation with high precision to the tumor or post-operative tumor bed, while limiting
dose to critical adjacent normal structures. This modality has been tested and found to be useless,
and possibly harmful in the primary management of glioblastoma [41–43]. Inadequate data exist to
assess its value in the management of inherently radioresistant (exposed to prior RT) malignant glioma
recurrences [42,44,45], but it appears to be useful for localized residual foci and recurrences of tumors
such as ependymomas and medulloblastoma [46]. SRS has become a popular treatment strategy for
non-infiltrative CNS tumors as well as brain metastases [47,48]. In the latter case, the toxic side effects
of whole brain radiation, which includes profound cognitive impairment, can be avoided by treating
patients with SRS, while not sacrificing local tumor control [49,50]. Nevertheless, for most primary
CNS neoplasms, conventionally fractionated radiotherapy remains the current standard of care [51].
3. Rationale for Pharmaceutical Radiosensitizers
An alternative strategy to combat brain tumor resistance to radiation therapy is through the
administration of tumor-specific radiosensitizing agents prior to or during radiation treatment in
order to enhance the sensitivity of the tumor target, while not affecting the intrinsic tolerance of in- or
near-field normal brain. A framework to characterize and understand potential interactions between
traditional chemotherapeutic agents and therapeutic ionizing radiation was described by Steel and
colleagues in 1979 [52,53]. The concept of synergy or supra-additivity emerged, as illustrated by the
classic isobologram described by Steel and Peckham [54].
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In the management of pediatric brain tumors, radiosensitization is desirable to accomplish dose
reduction, given the inherent adverse sensitivity of the developing brain, spine and encasing osseous
structures to ionizing radiation. Processes critical to neuronal development, cognition, Intelligence
Quotient (IQ), and achievement of developmental milestones can be severely impacted. Although the
prognosis of patients with medulloblastoma, the most common pediatric brain tumor, is in general very
good, with a 5 years tumor free survival of 75% to more than 95% in some subtypes [55], this population
suffers dramatically from the deleterious effects of radiation on the normal developing brain. Overall
normal development and growth are negatively impacted with the craniospinal irradiation used for this
disease. Decreased IQ and stunted skeletal growth and deformities, along with alopecia and hormonal
deficits, severely compromise the child’s quality of life far into adulthood [56]. A tumor-specific
radiosensitizer would be useful in this case to enable reduction of the craniospinal dose, while still
maintaining the high probability of cure currently afforded with modern therapy. Although adverse
effects on growth and development are not an issue in adult populations, targeted radiosensitization
is also desirable when treating adult patients with malignant CNS tumors to minimize the risk of
radionecrosis or other dose-related adverse side effects.
An example of a radiosensitizer currently used with concurrent radiotherapy as a standard of care
in the treatment of glioblastoma is temozolomide (TMZ). Through pioneering work conducted in the
1970s–1980s in the UK, the compound CCRG81045 gradually found its way into early phase I and II clinical
trials, where it was shown to be safe and effective in enhancing clinical and radiologic responses in small
groups of patients with GBM [57,58]. EORTC 26981, known colloquially as the “Stupp trial”, represented
the first phase III randomized trial where 573 patients with newly diagnosed GBM, after maximal safe
surgical resection, were treated concurrently with adjuvant radiation therapy to 60 Gy and daily TMZ
to a dose of 75 mg/m2, followed by 6 cycles of adjuvant monthly TMZ at a dose of 150–200 mg/m2
for 5 consecutive days per cycle vs. adjuvant RT alone. Median and 5 year-overall survival favored
the combined TMZ + radiation arm at 14.6 months vs. 12.1 months and 9.8 vs. 1.9%, respectively [59].
The mechanism of action through which TMZ radiosensitizes glioma cells is through the DNA damaging
effects of alkylation at O-6 of the guanine residue. Tumor cells can remove and repair this type of damage
through expression of O(6)-methylguanine-DNA methyltransferase (MGMT), thus escaping cell death.
However, hypermethylation of the MGMT promotor epigenetically silences the gene leaving cells sensitized
to the damaging effects of alkylating chemotherapy [60]. Screening for MGMT promoter methylation has
been shown to be prognostic for improved survival in response to therapy [60–62].
Identifying effective radiosensitizers requires an understanding of the underlying molecular
causes of radioresistance. Much progress has been made in this area and the remainder of this review
will summarize our current knowledge of the molecular causes of radioresistance.
4. Tumor Heterogeneity
Radioresistance is caused by a variety of factors that include the intrinsic biology that arises from
the aberrant genetic makeup of tumor cells, the extensive heterogeneity of brain tumors [63,64] and the
tumor microenvironment, which fosters and supports conditions that limit the response to radiation.
Tumors contain heterogeneous populations of stromal cells that support intermixed populations of
genetically divergent tumor cell populations, containing a minority of cancer stem cells (CSC) and
more differentiated cells that make up the tumor bulk. In this review we will use the term of CSC that
refers functionally to the tumor cell population with “stemness”, or the capacity to self-renew, generate
differentiated cells and sustain tumor proliferation [65]. Intratumoral heterogeneity is thought to
contribute to disease progression [66]. In particular, CSCs are thought to be in large part responsible
for the inherent radioresistance of a number of primary CNS tumors, including glial tumors and
medulloblastoma. Increasing evidence supports the notion that genetic diversity, epigenetics and tumor
microenvironment control stemness, which thereby influence patient responses to therapy [67,68].
The genetic diversity of some brain tumors is illustrated by several recent studies that suggest
a parallel evolution of genetically distinct subclones within a tumor. Surgical multisampling and
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molecular analysis of glioblastoma multiforme (GBM) tissues have demonstrated the presence of
multiple subclones within a single brain tumor that presumably arise through branching evolution [63].
In another study, single-cell RNA sequencing of GBM tissue revealed not only the presence of different
glioblastoma subtypes within a tumor, but also expression of diverse transcriptional programs related
to oncogenic signaling, proliferation, complement/immune response, and hypoxia [69]. In addition,
single cell analysis of GBM has revealed that different subclones have variable regenerative or stem
cell activity [70,71]. The response to genotoxic damage of these different populations may differ and
thus differentially impact the response to radiotherapy. CSCs, if not eradicated, can reconstitute a
tumor after treatment concludes.
An additional aspect of tumor complexity is provided by the inherent plasticity of tumor cells that
allows adaptation to intra- as well as extracellular changes. The recent identification of a core set of
neuro-developmental transcription factors (POU3F2, SOX2, SALL2, and OLIG2) that are sufficient to
fully reprogram differentiated GBM cells to “induced” tumor promoting cells, puts forth the possibility
of bidirectional plasticity through epigenetic reprogramming [72].
Another interesting recent finding that sheds a new light on therapeutic resistance of aggressive
brain tumors is the capacity of astrocytoma cells to form tumor microtubes (TM) that create
interconnected functional networks [73]. Osswald and colleagues demonstrated that this network of
microtubes helps tumor astrocytes to resist cell death by helping dissipating intracellular calcium waves
across gap junctions in this network. In addition, it was observed that this network is self-repairing,
which also largely protected the connected cells from cell death. Interestingly, down regulation of
Cx43, a specific connexin overexpressed in astrocytomas, caused loss of TM. On the other hand,
overexpression in oligodendroglioma cells of GAP-43, a protein highly expressed in axonal growth
cones, caused the formation of TM in these cells that normally lack them. Thus, Cx43 and GAP-43
could represent new targeting options to increase radiosentivity in astrocytoma.
The role of the microenvironment in sustaining stem cell-like programs in brain tumors has been
explored best in the context of the perivascular niche, where nitric oxide released by endothelial
cells induces a stem cell state in PDGF-induced gliomas via activation of the Notch pathway [74].
The perinecrotic niche has also been suggested to favor stemness via providing hypoxic conditions that
stimulate hypoxia-inducible factor 2a and consequent induction of specific tumor stem cell signature
genes [75,76]. Comparing the dispersal of radiation-induced γ´H2AX foci in primary GBM cells
grown in vitro and within intracerebral xenografts, Jamal and colleagues [77] observed a faster dispersal
in vivo, suggesting a greater capacity to repair DNA damage in vivo than in vitro. Together with data
on gene expression that indicated higher expression levels for genes involved in ROS metabolism and
antioxidant response in intracerebral xenografts than in vitro, these authors suggested that the brain
microenvironment protects GBM cells from radiation-induced DNA damage and facilitates its repair.
Several recent comprehensive reviews have described the properties of brain tumor CSCs, the
approaches taken to study them and the implications of CSCs for the development of new therapies,
as well as the role of the microenvironment in maintenance of glioma stem cells [65,78,79]. Here,
we will focus our discussion primarily on those characteristics of CSC that contribute to radioresistance
in brain tumors.
5. Enrichment of CSC by Ionizing Radiation (IR)
The enhanced resistance of CSC to radiation leads to preferential enrichment of this minor
subpopulation following radiation treatment. CD133+ brain tumor stem cells were in fact found to be
enriched in human glioma xenografts exposed to radiation [80]. These cells, isolated from irradiated
mouse cohorts, generated tumors faster than CD133´ populations. Rates of post-irradiation apoptosis
were lower in CD133+ cells compared to non-stem populations [80]. Another mechanism of CSC
enrichment by radiation has been hypothesized to be due to conversion of differentiated tumor cells
to stem-like cells, a process which may be stimulated by environmental stressors such as hypoxia
and radiotherapy [81]. In support of this, Dahan and colleagues observed an increase in neurosphere
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formation after exposure of differentiated glioblastoma cells to a sublethal dose of ionizing radiation
(IR) [82]. However, an alternative explanation of these findings could be that IR promoted a shift from
asymmetric to symmetric division of stem cells, as has been proposed to occur after temozolomide
treatment [83]. Although convincing proof of IR-induced dedifferentiation as a mechanism of CSC
enrichment is still lacking, dissection of the molecular underpinnings of this phenomenon could yield
novel targets for radiosensitization.
6. DNA Damage Response
The main mechanism through which radiotherapy kills tumor cells is by causing single and
double stranded DNA breaks, which, if not repaired, induce cell death. Actively dividing cells are
more susceptible to damage by radiation, with cells being most sensitive while in G2-M, less so in G1
and least radiosensitive in late S phase [84]. An important trait of CSCs is their slow rate of cell division
found in certain CSC populations in several tumor types [85]. Slow-cycling CSC have been found
also in glioblastoma where they have been implicated in resistance to genotoxic damage caused by
chemotherapy [85,86]. It is, thus, conceivable that this property of this type of cells may also contribute
to radioresistance in brain tumors.
In response to double-stranded DNA damage, cells mount a complex DNA damage response [87].
This is initiated by the MRN (MRE11-RAD50-NBS1) complex which senses double strand breaks
and activates the serine/threonine protein kinases ataxia telangiectasia mutated (ATM) and ataxia
telangiectasia and Rad3-related (ATR). These proteins then phosphorylate and activate the checkpoint
kinases Chk1 and Chk2, leading to cell cycle arrest, as well as a set of proteins that are involved in repairing
the DNA damage [88]. Glioblastoma CSCs are endowed with an enhanced response to DNA damage,
which contributes to their radioresistance [80]. GBM-derived CSCs have enhanced basal activity of DNA
damage response targets that include ATM, ATR, Chk1 and Chk2, which contribute to a stronger G2/M
checkpoint activation and subsequent DNA repair [89]. Bao and colleagues [80] showed that CD133+
GBM progenitor cells possess a robust response to DNA damage, which involves detection and repair
mechanisms that render them significantly more radioresistant than their differentiated counterparts.
ATM kinase inhibition was shown to lead to enhanced radiosensitization in glioblastoma CSCs [90].
Likewise, targeting Chk1 and Chk2 with the checkpoint kinase inhibitor debromohymenialdisine was
able to overcome radioresistance in CD133+ cells in both in vitro and in vivo [80].
Tumor cells that are genetically deficient in at least one DNA repair pathway can be sensitized
to radiation by targeting other redundant pathways [91]. This phenomenon is termed synthetic
lethality [92,93]. A key target to generate synthetic lethality is the enzyme poly [adenosine diphosphate
(ADP)] ribose polymerase (PARP). As a critical factor in the base excision repair (BER) pathway, PARP
is involved in the repair of single strand DNA breaks (SSB), part of the sublethal damage generated
after exposure to IR [94]. PARP recognizes the free ends of DNA and recruits other factors necessary
for repair to occur properly [95]. PARP inhibitors including ABT-888 (veliparib) [96–98], AZD-2281
and E7016 have been shown to cause in vitro and in vivo radiosensitization of glioma and are currently
being tested in phase I and II trials to assess treatment response in CNS tumors [99].
Although elements of either the DNA damage checkpoint response or DNA repair proteins are in
principle good targets for radiosensitization, simultaneous targeting of both pathways has been shown
to be more effective. Inhibition of ATM that affects both cell cycle checkpoint regulation and DNA
repair, achieved greater radiosensitization compared to inhibition of CHK1, ATR or PARP alone [100].
Thus, molecules that signal upstream of these responses may represent good therapeutic targets.
One such example is L1CAM (CD171), a CSC marker and cell surface adhesion protein that causes
phosphorylation and activation of ATM, Rad17, Chk1 and Chk2 after IR, enhancing the DNA damage
response. L1CAM also induces expression of NBS1, a member of the MRN complex that controls
cell cycle checkpoint as well as DNA repair after DNA damage. L1CAM down regulation sensitized
glioblastoma stem cells to radiation [101]. Thus, L1CAM signaling could provide a novel target to
overcome radiation resistance.
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Another signaling element that confers radioresistance by activating CHK2 in response to IR
is the stress activated protein MRK, also known as ZAK [102]. Although its involvement in CSC
radioresistance has not yet been explored, MRK has been shown to be activated by IR downstream
of ATM and NBS1 and to be necessary for complete activation of CHK2 and consequent cell cycle
arrest [103,104]. Interference with MRK expression by its down regulation, or inhibition of its activity
by a specific small molecule, in medulloblastoma cells leads to failure to arrest cell cycle division and
enhanced IR-induced cell death (RR, [105]).
In response to IR, p53 is implicated as a major regulator of radiation responsive genes that
are believed to contribute significantly to radioresistance. Adenovirus-mediated expression of p53
in glioblastoma cells has been shown to enhance radiosensitivity [106]. In vivo expression analysis
using the Olig2-TRAP transgenic system to examine transcription and translation simultaneously
on a genome-wide scale, have identified the p53 target gene cluster to be among the most robust
transcriptional and translational response clusters noted in proneural GBM in response to IR. These
findings provide support to the notion that p53 plays a key role in modulating the radioresistant
phenotype in glioblastoma by driving transcription of apoptotic gene expression programs and that of
genes that are involved in stress responses, including redox imbalances [107]. Thus, p53 mutations
or loss of wt p53 can cause radioresistance. As p53 is essential for the G1 checkpoint cell cycle arrest,
tumor cells that have lost its function rely on the S and G2/M checkpoints for stopping cell division
after IR. Therefore, an approach that has been explored to radiosensitize p53 mutant cell is to interfere
with elements that are responsible for the S and G2/M checkpoints. The use of Chk1 and PARP1
inhibitors have been shown to radiosensitize p53 mutant pancreatic cells and the ATM kinase inhibitor
KU-60019 preferentially sensitized p53-mutant glioma in vivo [108].
In addition to the DNA damage checkpoint proteins, an avenue that has been explored to prevent
cell cycle arrest after DNA damage has been the inactivation of regulators of the cyclin-CDK complex
that controls cell cycle progression. One such element is WEE1, a potent inhibitory kinase that directly
regulates cyclin-dependent kinase 1-mediated cell cycle progression through the G2/M phase into
mitosis. In response to DNA damage, cell division is halted by WEE1 to allow time for effective
DNA repair [109,110]. An in silico analysis found that WEE1 is highly expressed in high grade glioma
compared to normal brain tissue and siRNA-mediated depletion of WEE1 led to abrogation of G2
checkpoint-mediated cell cycle arrest and increased cell death [111]. Use of WEE1-selective inhibitors
such as AZD1775 (formerly MK-1775) has been shown to radiosensitize glioblastoma and diffuse
intrinsic pontine glioma cells and phase 1 clinical trials are now testing this in the clinic [109,112–114].
Radiation causes DNA damage by indirect energy transfer that produces chemically reactive free
radicals, including ROS. In addition to an effect on DNA, radiation may induce cell death via damage
of critical cellular structures like lipids and proteins [115]. Interestingly, low levels of ROS have been
found in CSCs and are attributed not only to lower production, but also to increased expression of
ROS scavenging systems, such as glutathione [116]. Thus, ROS scavenging systems might represent
novel targets to enhance radiation response.
7. Signaling Pathways
Intrinsic factors include survival signaling pathways that are deregulated through alterations
in growth factors or their receptors, up-regulation of pro-survival proteins, such as Bcl2 family
members, and changes in the DNA damage response and in metabolism. Although these pathways
are usually studied in isolation and in large part are considered to be independent, they are in fact
interrelated. Growth factor signaling for instance can lead to deregulated anti-apoptotic signals, as well
as improved DNA damage response [117,118]. The potential interactions among the different signaling
pathways may in fact contribute to escaping targeted therapeutic interventions that are aimed at
individual pathways.
Intracellular signaling is further modulated by signals contributed by the microenvironment
and conditions such as angiogenesis and hypoxia. The contribution of the microenvironment to
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maintenance of the stem cell phenotype has been extensively discussed in recent reviews [78,119].
In this capacity the microenvironment can enhance radioresistance of brain tumors. One of the
signaling pathways implicated in radioresistance in vivo is the one generated by the pleiotropic
cytokine transforming growth factor-β (TGF-β). Its inhibition by LY364947 or by LY109761, two small
molecule inhibitors of TGF-β type I receptor kinase, in combination with radiotherapy, has been shown
to interfere with DNA damage repair, thereby improving survival in preclinical studies [120,121].
Among the various cell types that comprise the microenvironment, microglia, the brain resident
macrophages, have also been shown to confer radioresistance to tumor cells. Inhibition of microglia
activation by semapimod was shown to sensitize glioblastoma tumors to ionizing radiation [122].
Another important problem recognized for decades in radiobiological research, is that of
intratumoral hypoxia and its role in radioresistance [123–125]. Strategies including the use of
hyperbaric oxygen to improve oxygen supply to tumors or drugs that specifically target and
radiosensitize hypoxic tumor cells have been exhaustively pursued [123,126–128]. However, it is
evident from Jens Overgaard’s 2007 meta-analysis of 82 hypoxic radiosensitization clinical trials
that the majority of trials evaluating CNS tumors treated with nitroimidazole-derived compounds as
potentially useful radiosensitizers failed to show any clinical benefit [129]. Other approaches have tried
to specifically target hypoxic cells in malignant gliomas with systemic therapies such as mitomycin
or tirapazamine that are more toxic to these hypoxic tumor cells than normoxic cells, but without
apparent clinical benefit [130,131]. Nevertheless, new data elucidating molecular networks responsible
for hypoxia-mediated radioresistance of CNS tumors are encouraging. They include the discovery
of potentially drugable targets upstream and downstream of hypoxia inducible factor-regulated
pathways [76,78,132,133].
Although the mechanisms through which the microenvironment supports radioresistance in
brain tumors largely remain to be elucidated, its importance is widely recognized and it continues to
be the subject of active studies. In the following chapters, we will focus our discussion on signaling
elements that directly contribute to radioresistance of cancer stem cells (see Figure 1 for a schematic of
the pathways discussed herein).
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7.1. Notch
One of the important signaling elements associated with maintenance of stemness is Notch and
its downstream pathway. This evolutionarily highly conserved pathway is initiated by binding of the
Notch receptor to its ligands on adjacent cells. This leads to Notch intracellular domain (NICD) release
after cleavage by γ secretase-like protease. NICD subsequently translocates into the nucleus and binds
to specific response elements to transactivate target genes [134]. Notch plays complex roles during
normal vertebrate neural development. It promotes neural stem cell survival and self-renewal [135]
and inhibits differentiation of neural progenitor cells into neurons [136]. However, Notch signaling
also promotes terminal differentiation of astrocytes from glial progenitor cells, while inhibiting the
differentiation of oligodendrocytes [136].
Early studies had shown that Notch blockade using a γ secretase inhibitor in medulloblastoma
cells depleted CD133+ cells, and treated cells showed diminished soft agar colony formation and
tumor growth, indicating that Notch signaling is necessary for the maintenance of medulloblastoma
stem cells [137]. Over the past decade, accumulating evidence also has shown a critical role for Notch
signaling in the maintenance of glioma stem cells [78,138]. In addition, analysis of Notch signaling
elements revealed increased expression of Notch ligands (DLL1, DLL3), Notch receptors (NOTCH1,
NOTCH2) and target genes (HES1, HES5, HEY1) in multiple primary tumors of the CNS including
astrocytoma, ependymoblastoma, oligodendroglioma, meningioma and GBM compared to normal
tissue matched controls [139]. Interestingly, proteomic analysis of a set of 27 surgical glioblastoma
samples revealed that activation of Notch signaling is highly correlated with EGFR activation [140],
a hallmark of the classical subtype of GBM tumors [141]. In line with this, Jagged1 is the most abundant
Notch ligand in GBM and its transcription is stimulated by EGFR variant III (EGFRvIII) [142]. We note,
however, that expression analysis of The Cancer Genome Atlas glioblastoma dataset also identified
high Notch activity in a subset of proneural-type GBM, correlating with high responsiveness to γ
secretase inhibitors [143], a discrepancy that may be due to the lack of correspondence between protein
levels and mRNA levels.
Importantly, the Notch pathway plays a critical role in the radioresistance of glioblastoma stem
cells. Interference with Notch signaling with a γ secretase inhibitor has been shown to impair clonogenic
survival of CD133+ stem cells, but not of CD133´ cells [144]. Knockdown of Notch1 or Notch2 also
increased the radiosensitivity of glioma stem cells. Notch-mediated radioprotection is thought to be
mediated in part by activation of the Akt and altering the balance between the truncated apoptotic
isoform of Mcl-1 (Mcl-1S) and Mcl-1L toward increased expression of the latter pro-survival protein [144].
The efficacy of γ-secretase inhibitors in the clinic remains to be evaluated.
7.2. Wnt/β-Catenin Pathway
Another pathway implicated in the maintenance of stem cells is the canonical Wnt/β-catenin
pathway, which is an important regulator of embryonic development as well as of adult stem cells and
it has been found to be altered in cancer [145,146]. Upon binding of Wnt ligands to receptors of the
Frizzled family and low density lipoprotein receptor-related protein/α2-macroglobulin family (LRP),
β-catenin is stabilized and translocates to the nucleus, where it activates the T-cell factor/lymphoid
enhancer factor (TCF/LEF) to transcribe Wnt target genes [146].
The Wnt/β-catenin pathway is involved in radioresistance of GBM in part through maintaining
the stem cell phenotype. This pathway was found to be activated within the stem cell population in
GBM orthotopic mouse models that had been treated with radiation. Inhibition of the Wnt pathway
led to decreased survival and clonogenicity of GBM cells, as well as reduction of the glioma stem
cell subpopulation [147]. Another potent oncogene, PLAGL2 (pleomorphic adenoma gene like 2),
a putative zinc finger transcription factor discovered on 20q11.21, a commonly amplified genomic
region in GBM, was identified as a Wnt-pathway activator that leads to suppression of both neural
stem cell and glioma initiating-cell differentiation. Thus, PLAGL2 acts as a powerful driver of stem
cell induction, maintenance and proliferation downstream of Wnt activation [148].
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Within glioma, Wnt and its cofactors are highly deregulated, contributing to increased
tumorigenicity. As an example, the Wnt family of embryonic lineage specifying genes, SFP1 and SFP2
(soluble Frizzled-related proteins) are often over-activated in glioma. It appears that these proteins
both promote glioma tumor growth and survival via enhanced clonogenicity and survival in the
absence of growth factors [149].
Control over Wnt signaling in glioma is often mediated in an epigenetic fashion. For example,
the gene promoters of Wnt pathway inhibitor genes, including soluble frizzled related proteins,
Dickkopf and naked genes, were found to be heavily methylated leading to epigenetic silencing [150].
In another study by Rheinbay and colleagues [151], an epigenomic analysis comparing chromatin
landscapes of GBM CSCs to human astrocytes, identified Achaete-Scute Complex-like 1 (ASCL1)
as an important activator of Wnt signaling from a list of aberrantly expressed genes normally kept
inactive by Polycomb receptors. ASCL1 removes the negative regulation of Wnt, normally imposed by
Dickkopf Wnt signaling pathway inhibitor 1 (DKK1), a process that was shown to be necessary for
glioma CSC tumorigenicity.
Other means of Wnt pathway deregulation in glioma involve FRAT1 (frequently rearranged in
advanced T cell lymphoma) that works to inhibit β-catenin phosphorylation by GSK. FRAT1, thus,
acts as a potent oncogene in the induction of Wnt signaling and positively correlates with increasing
grade of glioma [152,153]. Wnt-mediated tumorigenicity appears indeed to be β-catenin-dependent,
as shown by Wang and colleagues [154]. They showed that alteration of β-catenin activity via
suppression of pygopus 2 gene expression, a regulator of β-catenin/Tcf-mediated transcription
downstream of Wnt, leads to reduced cyclin D1 expression, thereby increasing cell cycle arrest in G1
and reducing cell proliferation. Not surprisingly, siRNA targeting of β-catenin, which is elevated in
immunohistochemical analysis of glioma specimens, also arrested cells in G1 and caused decreased
activation of c-Myc, c-jun and cyclin D1, while also inducing apoptotic cell death in glioma cells.
In glioma, key regulators of the Wnt/β-catenin pathway such as the ubiquitin-E3 ligase, Parkin
(PARK2) are often under-expressed or deleted. PARK2 is an ubiquitin-dependent negative regulator of
β-catenin and restoration of its function leads to the attenuation of glioma proliferation [155].
In contrast to GBM, Wnt pathway activation in medulloblastoma is associated with favorable
prognosis [156] and its exogenous expression in medulloblastoma cells contributes to increased
radiosensitivity [157].
7.3. SHH/Gli Pathway
A third signaling pathway implicated as a central mediator in the pathogenesis of glioma and
glioma stem cells (GSCs) is the Sonic Hedgehog (SHH). SHH binds to its transmembrane receptor
patched (PTCH) to release Smoothened (SMO) from PTCH mediated-inhibition, which in turn initiates
activation and nuclear translocation of Kruppel zinc finger transcription factor Gli1 [158–160]. Target
genes vital to “stemness” and self-renewal properties of GCSs are transactivated by the Gli family after
SHH activation [161]. Among these targets, insulin receptor substrate 1 (IRS1) appears to play a role in
IGF-mediated self- renewal of GSCs [162].
Up regulation of the Hedgehog signaling has been shown in glioblastoma and medulloblastoma,
and to a lesser extent, in neuroblastoma [163]. In medulloblastoma, SHH/Gli has been shown to
drive expression of stem cell modulator Bmi1, a key transcriptional polycomb repressor, found to
be overexpressed in medulloblastoma and in CD133+ tumor initiating progenitors [164–167]. Bmi1
is known to be vital to the sustained self-renewal and stemness properties of human GSCs [168].
Bmi1 has also been implicated in the DNA damage response pathway, both through regulation of
mitochondrial function with regard to the cellular redox state [169] and through modulation of DNA
double strand break repair efficacy by enabling targeted ubiquitination and degradation of γ-H2AX.
Loss of Bmi1 causes significant radiosensitization [170].
Sonic Hedgehog pathway blockade, established through treatment of medulloblastoma with
cyclopamine, resulted in neuronal differentiation and decreased stemness characteristics in vitro [171].
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In glioma, cyclopamine was shown to inhibit growth in cell lines expressing high levels of Gli1.
Cyclopamine treatment also diminished clonogenicity, arguing for the dependence of stemness on the
SHH/Gli1 pathway [172].
Because of the prominent role of the hedgehog pathway in cancer, and despite limited success so
far, several antagonists of this signaling cascade are still being tested in the clinic [173,174].
In addition to regulators of embryonic development like the ones described in the above sections,
a number of growth factors and their receptors have been strongly implicated in stem cells maintenance
and in radioresistance and are discussed below.
7.4. FGF-2
Fibroblast growth factor-2 belongs to the FGF superfamily that comprises 22 different genes.
FGF-2 signals primarily through the fibroblast growth factor receptors (FGFRs) FGFR-1 and FGFR-2,
which lead to activation of the Ras-MAPK and the PI3K-Akt pathways [175]. The derived signals
promote cellular growth and antagonize apoptosis. In glioma, FGF-2 contributes to maintenance of
glioma stem cells and it is used in the media that support their growth [176]. Growth factor withdrawal
resulted in differentiation of glioma stem cells, not observed in the presence of growth factor [177].
Lathia and colleagues [178] also observed that symmetrical division of glioma stem cells in vitro
depends on FGF-2 and that its removal favored differentiation.
Several studies have implicated fibroblast growth factor signaling in radioresistance. Early studies
revealed a role for FGF in the protection of endothelial cells from apoptosis [179], a process thought to be
dependent on protein kinase C-mediated signaling downstream of FGF [180]. Later, FGF-2-stimulated
radioresistance mechanisms were further elucidated by linking the small GTPase farnesylated RhoB as a
downstream mediator of radioprotection downstream of FGF-2 [181]. Inhibition of RhoB function by a
farnesyltransferase inhibitor was found to sensitize glioma cells to ionizing radiation [182]. In response to
IR, RhoB, along with αvβ3 and 5 via integrin-linked kinase signals protected against radiation-induced
mitotic cell death [183,184]. In addition, RhoB promoted γ´H2AX dephosphorylation and DNA double
strand breaks repair after IR exposure [185]. The FGF pathway is an attractive target for development
of radiosensitization agents to facilitate effective treatment of glioblastoma as its overexpression in
patient GBM tumor samples correlates with inferior survival. In fact, FGFR-1 has been identified as
an independent risk factor for poorer prognosis with decreased time to progression in patients whose
tumors express this receptor [186]. A small molecule designed to block FGFR has been shown to increase
progression free survival in mice with GBM in response to radiation, further confirming the importance
of the FGF pathway in radioresistance of brain tumors [187].
7.5. EGFR
During normal CNS development, the receptor tyrosine kinase, epidermal growth factor receptor
(EGFR) plays a major role in facilitating glial progenitor survival throughout gliogenesis. Transgenic
overexpression of the receptor suggested a role for EGFR in driving glial proliferation and in promoting
neural stem cell survival [188,189].
EGFR is frequently found to be amplified in highly proliferative tumors such as glioblastoma,
where it occurs in about 50% of cases [190]. Constitutive activation of EGFR signaling in glioblastoma
occurs also through deletion of exons 2–7 in the EGFR mRNA that leads to expression of the EGFRvIII
variant [191,192]. This constitutively active mutant receptor lacks part of the extracellular domain,
which renders it unable to bind ligands. It is found in approximately 40% of grade IV tumors with EGFR
amplification [192]. EGFR has been shown to support tumorigenicity primarily through signaling
toward downstream targets including RAS/RAF/MAPK and PI3-K/AKT pathways, which in turn
leads to increased proliferation, angiogenesis, migration and invasion of glioma cells [189,193].
There is strong evidence that antagonism of EGFR leads to radiosensitization in high grade
glioma. Early preclinical work using EGFR tyrosine kinase inhibitors, such as AG1478, or dominant
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negative constructs including EFGR-CD533, have all caused significant radiosensitization with dose
enhancement ratios approaching 1.85 [189,194–197].
Several clinical trials have tested various small molecule and antibody-based EGFR tyrosine
kinase inhibitors (TKIs), while vaccine-based and siRNA mediated EGFR targeting trials are now
underway. To take advantage of the radiosensitizing effects of EGFR attenuation seen in pre-clinical
models, phase I and II clinical trials designed to test the efficacy of an anti-EGFR monoclonal antibody
coupled to radioactive iodine (125I-mAb 425) have been conducted. Results from a large phase II trial
testing this strategy were encouraging with a median survival of 20.2 months when administered with
TMZ [198]. However, the EGFR TKIs gefitinib and erlotinib and the monoclonal antibodies cetuximab,
panitumamab and nimotuzumab, given adjuvantly, have failed to show efficacy in treating high-grade
glioma in clinical trials up to this point. This is due likely in large part to issues with blood brain barrier
permeability to the targeted agents and acquired resistance to EGFR inhibition [199]. In particular,
inherent resistance to these therapies is thought to be secondary to the glioma stem cell compartment’s
ability to activate alternative pathways to bypass EGFR upstream signals [200].
7.6. IGF
The role of insulin like growth factor signaling in radioresistance has been well established in
many extracranial tumor types. As alluded to in the sonic hedghog section, IGF signaling is necessary
for GSCs to maintain proliferative and self-renewal capacities downstream of SHH/Gli signaling.
In this context, the Gli transcription factor transactivates insulin receptor substrate I to drive MAPK
activation and to facilitate downstream GSC functions that include proliferation, self-renewal, invasion
and angiogenesis [162].
IGF-1 receptor signaling is important in glioma stem cell resistance to ionizing radiation.
Experiments done with murine glioma stem cells, exposed to fractionated radiation, showed upregulation
of IGF-1 receptor and increased IGF-1 secretion, leading to enhanced self-renewal of glioma stem cell
populations along with Akt activation. Furthermore, treatment with an IGF-1 receptor inhibitor resulted
in significant attenuation of AKT-mediated survival and subsequent radiosensitization [201]. Thus, IGF-1
receptor inhibitors may represent a new class of radiosensitizers for gliomas.
7.7. cMet
cMet is recognized as a neurotrophic protein, vital to the normal CNS development and to the
propagation of malignant gliomas [202]. cMet expression correlates with increased tumor grade [202,203].
Activation of its tyrosine kinase domain by binding of hepatocyte growth factor/scatter factor (HGF/SF)
in glioblastoma cells is thought to stimulate a more invasive phenotype and to promote tumor
angiogenesis [204]. cMet signaling reduces apoptosis in response to DNA damage triggered by ionizing
radiation, via phosphorylation of anti-apoptotic AKT signal transduction pathways [205]. Synergism
to induce greater GBM tumor cell killing has been shown with the combination of hypofractionated
ionizing radiation and SF/HGF/cMet blockade, via U1snRNA/ribozymes. This treatment also led to
decreased blood vessel formation within tumors [206,207].
Many of the signaling elements discussed above utilize common intracellular signals. Among
them, the PI3K/Akt/mTOR pathways have a central role in cell survival and in the response
to radiation.
7.8. PI3K/Akt Pathway
As mentioned in some of the previous sections, Akt is a key pro-survival signaling kinase
downstream of many growth factors and of oncogenic receptor tyrosine kinases [208,209].
Hyperactivation of Akt signaling has been correlated with worse progression-free survival and overall
survival in GBM patients [210–212]. Aberrant activation of Akt in GBM can occur as a result of loss of
PTEN suppressive function, which leads to unchecked proliferation through an array of pro-growth
and anti-apoptotic mechanisms [213,214]. In addition, the PI3K/Akt pathway can be abnormally
Cancers 2016, 8, 42 12 of 28
activated as a consequence of epidermal growth factor receptor (EGFR) gene amplification and
rearrangement, as well as CTMP promoter hypermethylation [215,216]. Importantly, Akt is required
for the maintenance of a stem-like state in glioma [217] and Akt inhibition increases their rate of
apoptosis and decreases the ability to form neurospheres [218,219]. Aberrant Akt activation has also
been observed in medulloblastoma [220].
Inhibition of Akt signaling in glioma cells has radiosensitizing effects [221]. Radiosensitization in
response to either Akt or PI3K inhibitors, or introduction of functional PTEN, has been demonstrated
in U87 glioma cells [222]. Similar radiosensitization was observed in primary patient-derived
glioblastoma cells, which were found to be sensitive to a low dose of an Akt inhibitor [223]. Thus,
Akt seems to be an attractive target for GBM therapy.
7.9. mTOR
Acting downstream of Akt, the mTOR serine/threonine protein kinase is a master regulator of cell
growth, proliferation, metabolism and autophagy, a cellular recycling and degradation system [224].
Signals propagated through mTOR originate from insulin growth factor receptor to affect amino
acid metabolism and transport. In this way, mTOR acts in response to the metabolic and nutritional
state of the cell and surrounding microenvironment. In the presence of ample supplies of extrinsic
amino acids, mTOR kinase activation increases anabolic cellular functions including translation
through S6K1-dependent phosphorylation and subsequent induction of eukaryotic initiation factor 4E
(4EBP1) [225].
The two major mTOR complexes, mTORC1 and mTORC2, play critical roles in the oncogenesis
of primary CNS neoplasms and contribute to radioresistance [226]. In pediatric gliomas, 80% of the
high-grade and 50% of low-grade gliomas have enhanced activation of two of the major downstream
targets of mTORC1, S6 and 4EBP1, which correlates with decrease in progression-free survival
independently of tumor grade [227].
The mTOR pathway has been shown to be highly activated in medulloblastoma stem cells within
the perivascular niche after radiation and Akt inhibition in this model sensitized cells within this niche
to radiation-induced apoptosis [228]. A radioresistant phenotype has also been observed in glioma
cells through an mTOR-dependent autophagy [229]. Inhibition of autophagy in glioblastoma cells,
using a dual pI3K/ mTOR inhibitor (NVP-BEZ235), led to increased radiosensitization in both in vitro
and in vivo glioma models [230–232]. Work from Lomonaco and colleagues shows autophagy to be
increased in IR-resistant clones derived from treated glioblastoma cancer stem cells [233]. However, the
notion that autophagy causes greater radioresistance is still controversial, as Nam and colleagues [234]
reported that mTOR inhibition-dependent enhancement of autophagy in glioma cells, after exposure
to ionizing radiation, leads to reduced tumor size, which was caused by premature cellular senescence.
The hypoxic microenvironment within GBM leads to resistance to ionizing radiation. This has
been found to be in part secondary to mTOR-dependent inhibition of translation, via modulation of
eukaryotic initiation factor for E (EIF4E), the key factor involved in cap-dependent protein translation.
Bypassing mTOR repression, via overexpression of EIF4E, leads to enhanced radiosensitivity and
selective loss of the hypoxic cell population [235].
Despite promising pre-clinical data, recent phase I and II clinical trials using mTOR pathway
inhibitors, including temsirolimus monotherapy, have failed to demonstrate improved overall survival
in recurrent glioma patients, although various radiographic responses were observed [236]. Two phase
I trials combining temozolomide with mTOR inhibitors and concurrent radiotherapy have been
conducted, showing the treatment to be well tolerated with decreases in tumor metabolism noted on
PETCT-based imaging [237,238]. These disappointing results may be explained in part by pre-clinical
and phase I data that have suggested potential loss of negative feedback regulation over Akt,
derived from the use of mTOR inhibitors alone or combined with standard chemoradiotherapy
in the treatment of high grade glioma. This observation provides support for the employment of
dual PI3K/mTOR inhibitors [239]. Indeed, pre-clinical data generated using dual inhibitors have
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justified a currently ongoing phase I clinical trial combining dual PI3K/mTOR inhibitor XL765
with concurrent chemoradiation [239–241]. Further support for combined inhibition of multiple
interconnected pathways is provided by work done in GBM with blockade of endogenous EGFR
activity concomitantly with mTOR inhibition, leading to enhanced radiosensitivity mediated through
pro-death autophagy [242].
Finally, downstream of intracellular signaling elements, transcription factors are responsible for
regulation of gene expression and for implementing new cell programs. Here we review the role of
two crucial transcription factors in establishing radioresistance.
7.10. NF-κB
Classically, nuclear factor-kappaB (NF-κB) functions as a transcription factor kept under tight
cytoplasmic regulation by the kappa B inhibitor protein, IκB. Upon ligand binding of a cell surface receptor
such as TNF-R or Toll-like receptor, IκB is targeted for proteosomal degradation via IKK complex-mediated
phosphorylation, thus releasing NF-κB to translocate into the nucleus and transactivate downstream
target genes [243].
NF-κB activation was recently shown to contribute via MLK4 to the development of intratumoral
heterogeneity and enhanced radioresistance of glioblastoma by inducing a transition from a proneural
to mesenchymal transcriptional GBM subtype [244,245]. Furthermore, radiation-dependent TNFα
activation is able to enhance NF-κB-mediated radioresistance, while inhibition of NF-κB signaling
promotes TNFα-mediated apoptosis in response to the radiomimetic neocarzinostatin via p53-dependent
TIGAR activation [246]. In response to radiation, NF-κB is thought to promote resistance to
radiation-induced cell death downstream of PI3K/AKT via the promotion of anti-apoptotic genes
such as Bcl-2 and Bcl-XL [247]. For example, in response to ionizing radiation induced- DNA-damage,
NF-κB is activated to drive the expression of IL-6, IL-8 and Bcl-XL and promotes GBM proliferation via a
miR-181b-mediated positive feedback loop, which enhances NF-κB activity downstream of IR [248].
Early in vitro attempts at targeting NF-κB activity in GBM have been successful in decreasing
tumor cell proliferation. One approach targeted tumors cells with poly (DL-lactic-co-glycolic acid)
(PLGA) microparticle-containing NF-κB decoy oligonucleotides possessing DNA-binding sites specific
for the wild-type NF-κB DNA-binding domain. Release of the decoy oligonucleotides within the
cell acts to bind up free NF-κB, thus effectively inhibiting transactivation of downstream target
genes, leading to inhibition of GBM cell growth and proliferation [249,250]. Other selective NF-κB
inhibitors include dehydroxymethylepoxyquinomicin that in combination with temozolomide (TMZ)
was shown to synergistically sensitize cells to radiation [251]. Additionally, a phase I/II clinical
trial utilizing the NF-κB inhibitor, sulfasalazine was recently closed after an interim analysis failed
to demonstrate efficacy when used as second-line monotherapy in the treatment of patients with
recurrent GBM [252,253]. However, trials looking at a combined approach with radiation have not yet
been carried out.
7.11. STAT3
STAT3 functions at the confluence of several important molecular pathways involved in
radioresistance of brain tumors, including Wnt, Notch, Akt and the Bcl2, Bcl-xL and Mcl-1 survival
genes [254]. STAT3 is a transcription factor that acts downstream of the gp130 receptor upon binding
to IL-6. Receptor activation leads to STAT3 phosphorylation, dimerization and translocation into
the nucleus, where it transactivates pro-survival genes such as c-Myc, Bcl-xL, MCl-1, and survivin
to promote cell proliferation [255–257]. STAT3 can also be activated downstream of other receptors,
including EGFR, as well as by receptor-associated kinases such as JAK2 and Src [258–260]. STAT3 has
been shown to be constitutively activated in gliomas and medulloblastomas [261–264].
STAT3 is also implicated as a key driver in the proneural to mesenchymal shift seen in GBM
after exposure to RT, which contributes to a radioresistant phenotype [107]. Phosphorylation of
serine 727 is important for STAT3-mediated resistance to ionizing radiation in glioma and, thus,
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disrupting phosphorylation at this site could provide a potential target for radiosensitization [265].
Novel inhibitors targeting STAT3 have been rationally designed, such as FLLL32. This molecule,
modified from curcumin, leads to significant decreases in S727-STAT3 phosphorylation in established
glioblastoma cell lines [266]. The Jack2 inhibitor, AG490, as well as resveratrol, were shown to inhibit
not only the stem-like properties of GBM cells, but also to reduce their radioresistance in vitro and
in vivo [267]. Thus, both molecules could have therapeutic benefits in the clinic.
8. Conclusions
Our understanding of the molecular mechanisms that promote radioresistance has revealed a
number of potential targets, inhibitors of which could be developed as radiosensitizers. A number of
these inhibitors have been tested in the clinic as monotherapy and shown very disappointing results.
As it is expected that their benefit as radiosensitizers depends on their concurrent use with radiation,
new clinical trials that evaluate these agents in conjunction with radiotherapy will be necessary.
The understanding that cancer stem cells represent a source of therapy resistance and failure has
suggested that targeting this cell population within the tumor will provide increased sensitization
to radiotherapy as well. Thus, together with optimized radiation delivery modalities, advances
in identification of radioresistance targets and development of their inhibitors may provide better
future therapeutic outcomes for brain tumors. Therapeutic success of small molecule radiosensitizers
will depend also on their ability to cross the blood brain barrier, which represents an outstanding
challenge in brain tumor treatments. Thus, development of novel delivery modalities that overcome
this obstacle will be crucial to improving therapies for brain tumors. As several chemotherapies
work by causing DNA damage, it is expected that novel radiosensitizers may be effective also to
overcome chemoresistance.
Acknowledgments: This work was supported by the following funds: Swim Across America Foundation and
Project To Cure Foundation to Marc Symons and the Bradley Zankel Foundation to Rosamaria Ruggieri.
Author Contributions: All authors contributed to the writing and editing of the review.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Brandsma, D.; Stalpers, L.; Taal, W.; Sminia, P.; van Den Bent, M.J. Clinical features, mechanisms, and
management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008, 9, 453–461. [CrossRef]
2. Siu, A.; Wind, J.J.; Iorgulescu, J.B.; Chan, T.A.; Yamada, Y.; Sherman, J.H. Radiation necrosis following
treatment of high grade glioma—A review of the literature and current understanding. Acta Neurochir. (Wien).
2012, 154, 191–201. [CrossRef] [PubMed]
3. Li, Y.Q.; Chen, P.; Haimovitz-Friedman, A.; Reilly, R.M.; Wong, C.S. Endothelial apoptosis initiates acute
blood-brain barrier disruption after ionizing radiation. Cancer Res. 2003, 63, 5950–5956. [PubMed]
4. Chiang, C.S.; Hong, J.H.; Stalder, A.; Sun, J.R.; Withers, H.R.; McBride, W.H. Delayed molecular responses to
brain irradiation. Int. J. Radiat. Biol. 1997, 72, 45–53. [CrossRef] [PubMed]
5. Hong, J.H.; Chiang, C.S.; Campbell, I.L.; Sun, J.R.; Withers, H.R.; McBride, W.H. Induction of acute phase
gene expression by brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1995, 33, 619–626. [CrossRef]
6. Rodel, F.; Frey, B.; Multhoff, G.; Gaipl, U. Contribution of the immune system to bystander and non-targeted
effects of ionizing radiation. Cancer Lett. 2015, 356, 105–113. [CrossRef] [PubMed]
7. Sprung, C.N.; Ivashkevich, A.; Forrester, H.B.; Redon, C.E.; Georgakilas, A.; Martin, O.A. Oxidative DNA
damage caused by inflammation may link to stress-induced non-targeted effects. Cancer Lett. 2015, 356,
72–81. [CrossRef] [PubMed]
8. Havaki, S.; Kotsinas, A.; Chronopoulos, E.; Kletsas, D.; Georgakilas, A.; Gorgoulis, V.G. The role of oxidative
DNA damage in radiation induced bystander effect. Cancer Lett. 2015, 356, 43–51. [CrossRef] [PubMed]
9. Martin, A.; Martin, M.; Linan, O.; Alvarenga, F.; Lopez, M.; Fernandez, L.; Buchser, D.; Cerezo, L. Bystander
effects and radiotherapy. Rep. Pract. Oncol. Radiother. 2015, 20, 12–21. [CrossRef] [PubMed]
Cancers 2016, 8, 42 15 of 28
10. Zelefsky, M.J.; Pei, X.; Chou, J.F.; Schechter, M.; Kollmeier, M.; Cox, B.; Yamada, Y.; Fidaleo, A.; Sperling, D.;
Happersett, L.; et al. Dose escalation for prostate cancer radiotherapy: Predictors of long-term biochemical
tumor control and distant metastases-free survival outcomes. Eur. Urol. 2011, 60, 1133–1139. [CrossRef]
[PubMed]
11. Kawaguchi, K.; Sato, K.; Horie, A.; Iketani, S.; Yamada, H.; Nakatani, Y.; Sato, J.; Hamada, Y. Stereotactic
radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma.
Radiat. Oncol. 2010, 5, 51–59. [CrossRef] [PubMed]
12. Unger, K.R.; Lominska, C.E.; Deeken, J.F.; Davidson, B.J.; Newkirk, K.A.; Gagnon, G.J.; Hwang, J.; Slack, R.S.;
Noone, A.M.; Harter, K.W. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer.
Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 1411–1419. [CrossRef] [PubMed]
13. Khoo, V.S. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin. Oncol.
2005, 17, 560–571. [CrossRef]
14. Kuban, D.A.; Tucker, S.L.; Dong, L.; Starkschall, G.; Huang, E.H.; Cheung, M.R.; Lee, A.K.; Pollack, A.
Long-Term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat.
Oncol. Biol. Phys. 2008, 70, 67–74. [CrossRef] [PubMed]
15. Timmerman, R.; Paulus, R.; Galvin, J.; Michalski, J.; Straube, W.; Bradley, J.; Fakiris, A.; Bezjak, A.; Videtic, G.;
Johnstone, D.; et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010,
303, 1070–1076. [CrossRef] [PubMed]
16. Tsien, C.; Moughan, J.; Michalski, J.M.; Gilbert, M.R.; Purdy, J.; Simpson, J.; Kresel, J.J.; Curran, W.J.; Diaz, A.;
Mehta, M.P. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed
glioblastoma: Radiation Therapy Oncology Group trial 98-03. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73,
699–708. [CrossRef] [PubMed]
17. Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus
Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly
Diagnosed Glioblastoma. Available online: https://clinicaltrials.gov/ct2/show/NCT02179086 (accessed on
25 March 2016).
18. Prasanna, A.; Ahmed, M.M.; Mohiuddin, M.; Coleman, C.N. Exploiting sensitization windows of opportunity
in hyper and hypofractionated radiation therapy. J. Thorac. Dis. 2014, 6, 287–302. [PubMed]
19. Lee, D.Y.; Chunta, J.L.; Park, S.S.; Huang, J.; Martinez, A.A.; Grills, I.S.; Krueger, S.A.; Wilson, G.D.; Marples, B.
Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic
model of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86, 978–985. [CrossRef] [PubMed]
20. Beauchesne, P.; Bernier, V.; Carnin, C.; Taillandier, L.; Djabri, M.; Martin, L.; Michel, X.; Maire, J.P.; Khalil, T.;
Kerr, C.; et al. Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times
daily ultrafractionated radiation therapy. Neuro-oncology 2010, 12, 595–602. [CrossRef] [PubMed]
21. Leder, K.; Pitter, K.; Laplant, Q.; Hambardzumyan, D.; Ross, B.D.; Chan, T.A.; Holland, E.C.; Michor, F.
Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell
2014, 156, 603–616. [CrossRef] [PubMed]
22. Simpson, W.J.; Platts, M.E. Fractionation study in the treatment of glioblastoma multiforme. Int. J. Radiat.
Oncol. Biol. Phys. 1976, 1, 639–644. [CrossRef]
23. Payne, D.G.; Simpson, W.J.; Keen, C.; Platts, M.E. Malignant astrocytoma: Hyperfractionated and standard
radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer 1982, 50, 2301–2306.
[CrossRef]
24. Coughlin, C.; Scott, C.; Langer, C.; Coia, L.; Curran, W.; Rubin, P. Phase II, two-arm RTOG trial (94-11) of
bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor
volume (>20 or < or = 20 cm (2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible.
Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 1351–1358. [PubMed]
25. Lustig, R.A.; Seiferheld, W.; Berkey, B.; Yung, A.W.; Scarantino, C.; Movsas, B.; Jones, C.U.; Simpson, J.R.;
Fishbach, J.; Curran, W.J., Jr. Imaging response in malignant glioma, RTOG 90-06. Am. J. Clin. Oncol. 2007,
30, 32–37. [CrossRef] [PubMed]
26. Werner-Wasik, M.; Scott, C.B.; Nelson, D.F.; Gaspar, L.E.; Murray, K.J.; Fischbach, J.A.; Nelson, J.S.;
Weinstein, A.S.; Curran, W.J. Final report of a phase I/II trial of hyperfractionated and accelerated
hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas.
Radiation Therapy Oncology Group Study 83-02. Cancer 1996, 77, 1535–1543. [CrossRef]
Cancers 2016, 8, 42 16 of 28
27. Knisely, J.P.S.; Yue, N.; Chen, Z.; Nath, R.; Trumpore, S.; Duncan, J.S.; Studholme, C. Automatic three
dimensional co-registration of diagnostic MRI and treatment planning CT for brain tumor radiotherapy
treatment planning. Int. J. Radiat. Oncol. Biol. Phys. 1999. [CrossRef]
28. Herman, M.G.; Pisansky, T.M.; Kruse, J.J.; Prisciandaro, J.I.; Davis, B.J.; King, B.F. Technical aspects of daily
online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal
imaging device. Int. J. Radiat. Oncol. Biol. Phys. 2003, 57, 1131–1140. [CrossRef]
29. Guckenberger, M.; Sweeney, R.A.; Flickinger, J.C.; Gerszten, P.C.; Kersh, R.; Sheehan, J.; Sahgal, A.
Clinical practice of image-guided spine radiosurgery—-results from an international research consortium.
Radiat. Oncol. 2011, 6, 172–183. [CrossRef] [PubMed]
30. Cox, B.W.; Spratt, D.E.; Lovelock, M.; Bilsky, M.H.; Lis, E.; Ryu, S.; Sheehan, J.; Gerszten, P.C.; Chang, E.;
Gibbs, I.; et al. International spine radiosurgery consortium consensus guidelines for target volume definition
in spinal stereotactic radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 2012, 83, 597–605. [CrossRef] [PubMed]
31. Bowden, P.J.; See, A.W.; Dally, M.J.; Bittar, R.G. Stereotactic radiosurgery for brain and spine metastases.
J. Clin. Neurosci. 2014, 21, 731–734. [CrossRef] [PubMed]
32. Scoccianti, S.; Detti, B.; Gadda, D.; Greto, D.; Furfaro, I.; Meacci, F.; Simontacchi, G.; Di Brina, L.; Bonomo, P.;
Giacomelli, I.; et al. Organs at risk in the brain and their dose-constraints in adults and in children: A radiation
oncologist’s guide for delineation in everyday practice. Radiother. Oncol. 2015, 114, 230–238. [CrossRef]
[PubMed]
33. Van Baardwijk, A.; Bosmans, G.; Bentzen, S.M.; Boersma, L.; Dekker, A.; Wanders, R.; Wouters, B.G.;
Lambin, P.; de Ruysscher, D. Radiation dose prescription for non-small-cell lung cancer according to normal
tissue dose constraints: An in silico clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71, 1103–1110.
[CrossRef] [PubMed]
34. Brown, J.M.; Carlson, D.J.; Brenner, D.J. The tumor radiobiology of SRS and SBRT: Are more than the 5 Rs
involved? Int. J. Radiat. Oncol. Biol. Phys. 2014, 88, 254–262. [CrossRef] [PubMed]
35. Okunieff, P.; Petersen, A.L.; Philip, A.; Milano, M.T.; Katz, A.W.; Boros, L.; Schell, M.C. Stereotactic Body
Radiation Therapy (SBRT) for lung metastases. Acta Oncol. 2006, 45, 808–817. [CrossRef] [PubMed]
36. Song, C.W.; Kim, M.S.; Cho, L.C.; Dusenbery, K.; Sperduto, P.W. Radiobiological basis of SBRT and SRS. Int. J.
Clin. Oncol. 2014, 19, 570–578. [CrossRef] [PubMed]
37. Onishi, H.; Shirato, H.; Nagata, Y.; Hiraoka, M.; Fujino, M.; Gomi, K.; Karasawa, K.; Hayakawa, K.; Niibe, Y.;
Takai, Y.; et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: Can
SBRT be comparable to surgery? Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, 1352–1358. [CrossRef] [PubMed]
38. Wolff, D.; Stieler, F.; Welzel, G.; Lorenz, F.; Abo-Madyan, Y.; Mai, S.; Herskind, C.; Polednik, M.; Steil, V.;
Wenz, F.; et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and
3D-conformal RT for treatment of prostate cancer. Radiother. Oncol. 2009, 93, 226–233. [CrossRef] [PubMed]
39. Chin, E.; Loewen, S.K.; Nichol, A.; Otto, K. 4D VMAT, gated VMAT, and 3D VMAT for stereotactic body
radiation therapy in lung. Phys. Med. Biol. 2013, 58, 749–770. [CrossRef] [PubMed]
40. Clark, G.M.; Popple, R.A.; Young, P.E.; Fiveash, J.B. Feasibility of single-isocenter volumetric modulated Arc
radiosurgery for treatment of multiple brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76, 296–302.
[CrossRef] [PubMed]
41. Cardinale, R.; Won, M.; Choucair, A.; Gillin, M.; Chakravarti, A.; Schultz, C.; Souhami, L.; Chen, A.;
Pham, H.; Mehta, M. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost
for supratentorial glioblastoma multiforme: RTOG 0023. Int. J. Radiat. Oncol. Biol. Phys. 2006, 65, 1422–1428.
[CrossRef] [PubMed]
42. Tsao, M.N.; Mehta, M.P.; Whelan, T.J.; Morris, D.E.; Hayman, J.A.; Flickinger, J.C.; Mills, M.; Rogers, C.L.;
Souhami, L. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review
of the role of radiosurgery for malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63, 47–55. [CrossRef]
[PubMed]
43. Souhami, L.; Seiferheld, W.; Brachman, D.; Podgorsak, E.B.; Werner-Wasik, M.; Lustig, R.; Schultz, C.J.;
Sause, W.; Okunieff, P.; Buckner, J.; et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with
glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int. J. Radiat. Oncol.
Biol. Phys. 2004, 60, 853–860. [CrossRef] [PubMed]
Cancers 2016, 8, 42 17 of 28
44. Elaimy, A.L.; Mackay, A.R.; Lamoreaux, W.T.; Demakas, J.J.; Fairbanks, R.K.; Cooke, B.S.; Lamm, A.F.;
Lee, C.M. Clinical outcomes of gamma knife radiosurgery in the salvage treatment of patients with recurrent
high-grade glioma. World Neurosurg. 2013, 80, 872–878. [CrossRef] [PubMed]
45. Larson, D.A.; Prados, M.; Lamborn, K.R.; Smith, V.; Sneed, P.K.; Chang, S.; Nicholas, K.M.; Wara, W.M.;
Devriendt, D.; Kunwar, S.; et al. Phase II study of high central dose Gamma Knife radiosurgery and
marimastat in patients with recurrent malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 1397–1404.
[CrossRef]
46. Murphy, E.S.; Chao, S.T.; Angelov, L.; Vogelbaum, M.A.; Barnett, G.; Jung, E.; Recinos, V.R.; Mohammadi, A.;
Suh, J.H. Radiosurgery for Pediatric Brain Tumors. Pediatr. Blood Cancer 2016, 63, 398–405. [CrossRef]
[PubMed]
47. Kondziolka, D.; Flickinger, J.; Lunsford, L.D. Radiosurgery for brain metastases. Prog. Neurol. Surg. 2012, 25,
115–122. [PubMed]
48. Minniti, G.; Amichetti, M.; Enrici, R.M. Radiotherapy and radiosurgery for benign skull base meningiomas.
Radiat. Oncol. 2009. [CrossRef] [PubMed]
49. Kocher, M.; Wittig, A.; Piroth, M.D.; Treuer, H.; Seegenschmiedt, H.; Ruge, M.; Grosu, A.L.; Guckenberger, M.
Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on
Stereotactic Radiotherapy. Strahlenther. Onkol. 2014, 190, 521–532. [CrossRef] [PubMed]
50. Aoyama, H.; Shirato, H.; Onimaru, R.; Kagei, K.; Ikeda, J.; Ishii, N.; Sawamura, Y.; Miyasaka, K.
Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary
and oligo brain metastasis using noninvasive fixation of the skull. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56,
793–800. [CrossRef]
51. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.;
Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N. Engl. J. Med. 2005, 352, 987–996. [CrossRef] [PubMed]
52. Wilson, G.D.; Bentzen, S.M.; Harari, P.M. Biologic basis for combining drugs with radiation.
Semin. Radiat. Oncol. 2006, 16, 2–9. [CrossRef] [PubMed]
53. Steel, G.G. Terminology in the description of drug-radiation interactions. Int. J. Radiat. Oncol. Biol. Phys.
1979, 5, 1145–1150. [CrossRef]
54. Steel, G.G.; Peckham, M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept
of additivity. Int. J. Radiat. Oncol. Biol. Phys. 1979, 5, 85–91. [CrossRef]
55. Brandes, A.A.; Bartolotti, M.; Marucci, G.; Ghimenton, C.; Agati, R.; Fioravanti, A.; Mascarin, M.; Volpin, L.;
Ammannati, F.; Masotto, B.; et al. New perspectives in the treatment of adult medulloblastoma in the era of
molecular oncology. Crit. Rev. Oncol. Hematol. 2015, 94, 348–359. [CrossRef] [PubMed]
56. Edelstein, K.; Spiegler, B.J.; Fung, S.; Panzarella, T.; Mabbott, D.J.; Jewitt, N.; D’Agostino, N.M.; Mason, W.P.;
Bouffet, E.; Tabori, U.; et al. Early aging in adult survivors of childhood medulloblastoma: Long-term
neurocognitive, functional, and physical outcomes. Neuro-oncology 2011, 13, 536–545. [CrossRef] [PubMed]
57. Newlands, E.S.; Blackledge, G.R.; Slack, J.A.; Rustin, G.J.; Smith, D.B.; Stuart, N.S.; Quarterman, C.P.;
Hoffman, R.; Stevens, M.F.; Brampton, M.H. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC
362856). Br. J. Cancer 1992, 65, 287–291. [PubMed]
58. Bower, M.; Newlands, E.S.; Bleehen, N.M.; Brada, M.; Begent, R.J.H.; Calvert, H.; Colquhoun, I.; Lewis, P.;
Brampton, M.H. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade
glioma. Cancer Chemother. Pharmacol. 1997, 40, 484–488. [CrossRef] [PubMed]
59. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.;
Fisher, B.; Belanger, K.; et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the
EORTC-NCIC trial. Lancet Oncol. 2009, 10, 459–466. [CrossRef]
60. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.;
Mason, W.; Mariani, L.; et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl.
J. Med. 2005, 352, 997–1003. [CrossRef] [PubMed]
61. Khosla, D. Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann. Transl. Med.
2016, 4, 2–9.
62. He, Z.; Ping, Y.; Xu, S.; Lin, Y.; Yu, S.; Kung, H.; Bian, X. Lower MGMT expression predicts better prognosis
in proneural-like glioblastoma. Int. J. Exp. Med. 2015, 8, 20287–20294.
Cancers 2016, 8, 42 18 of 28
63. Sottoriva, A.; Spiteri, I.; Piccirillo, S.G.M.; Touloumis, A.; Collins, V.P.; Marioni, J.C.; Curtis, C.; Watts, C.;
Tavaré, S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl.
Acad. Sci. USA 2013, 110, 4009–4014. [CrossRef] [PubMed]
64. Hoffman, L.M.; Dewire, M.; Ryall, S.; Buczkowicz, P.; Leach, J.; Miles, L.; Ramani, A.; Brudno, M.; Kumar, S.S.;
Drissi, R.; et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma:
Implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol. Commun. 2016. [CrossRef]
65. Lathia, J.D.; Mack, S.C.; Mulkearns-Hubert, E.E.; Valentim, C.L.L.; Rich, J.N. Cancer stem cells in glioblastoma.
Genes Dev. 2015, 29, 1203–1217. [CrossRef] [PubMed]
66. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
[PubMed]
67. Bedard, P.L.; Hansen, A.R.; Ratain, M.J.; Siu, L.L. Tumour heterogeneity in the clinic. Nature 2013, 501,
355–364. [CrossRef] [PubMed]
68. Kreso, A.; Dick, J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14, 275–291. [CrossRef]
[PubMed]
69. Patel, A.P.; Tirosh, I.; Trombetta, J.J.; Shalek, A.K.; Gillespie, S.M.; Wakimoto, H.; Cahill, D.P.; Nahed, B.V.;
Curry, W.T.; Martuza, R.L.; et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary
glioblastoma. Science 2014, 344, 1396–1401. [CrossRef] [PubMed]
70. Piccirillo, S.G.M.; Combi, R.; Cajola, L.; Patrizi, A.; Redaelli, S.; Bentivegna, A.; Baronchelli, S.; Maira, G.;
Pollo, B.; Mangiola, A.; et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas
and display different tumorigenicity and independent genomic evolution. Oncogene 2009, 28, 1807–1811.
[CrossRef] [PubMed]
71. Piccirillo, S.G.M.; Colman, S.; Potter, N.E.; van Delft, F.W.; Lillis, S.; Carnicer, M.J.; Kearney, L.; Watts, C.;
Greaves, M. Genetic and functional diversity of propagating cells in glioblastoma. Stem Cell Reports 2015, 4,
7–15. [CrossRef] [PubMed]
72. Suvà, M.L.; Rheinbay, E.; Gillespie, S.M.; Patel, A.P.; Wakimoto, H.; Rabkin, S.D.; Riggi, N.; Chi, A.S.;
Cahill, D.P.; Nahed, B.V.; et al. Reconstructing and reprogramming the tumor-propagating potential of
glioblastoma stem-like cells. Cell 2014, 157, 580–594. [CrossRef] [PubMed]
73. Osswald, M.; Jung, E.; Sahm, F.; Solecki, G.; Venkataramani, V.; Blaes, J.; Weil, S.; Horstmann, H.; Wiestler, B.;
Syed, M.; et al. Brain tumour cells interconnect to a functional and resistant network. Nature 2015, 528, 93–98.
[CrossRef] [PubMed]
74. Charles, N.; Ozawa, T.; Squatrito, M.; Bleau, A.M.; Brennan, C.W.; Hambardzumyan, D.; Holland, E.C.
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced
glioma cells. Cell Stem Cell 2010, 6, 141–152. [CrossRef] [PubMed]
75. Heddleston, J.M.; Li, Z.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. The hypoxic microenvironment
maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.
Cell Cycle 2009, 8, 3274–3284. [CrossRef] [PubMed]
76. Seidel, S.; Garvalov, B.K.; Wirta, V.; von Stechow, L.; Schänzer, A.; Meletis, K.; Wolter, M.; Sommerlad, D.;
Henze, A.T.; Nistér, M.; et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible
factor 2α. Brain 2010, 133, 983–995. [CrossRef] [PubMed]
77. Jamal, M.; Rath, B.H.; Williams, E.S.; Camphausen, K.; Tofilon, P.J. Microenvironmental regulation of
glioblastoma radioresponse. Clin. Cancer Res. 2010, 16, 6049–6059. [CrossRef] [PubMed]
78. Schonberg, D.L.; Lubelski, D.; Miller, T.E.; Rich, J.N. Brain tumor stem cells: Molecular characteristics and
their impact on therapy. Mol. Aspects Med. 2014, 39, 82–101. [CrossRef] [PubMed]
79. Herold-mende, C.; Mock, A. Microenvironment and brain tumor stem cell maintenance: Impact of the niche.
Anticancer Agents Med. Chem. 2014, 14, 1065–1074. [CrossRef] [PubMed]
80. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N.
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature
2006, 444, 756–760. [CrossRef] [PubMed]
81. Charles, N.; Holland, E.C. Brain tumor treatment increases the number of cancer stem-like cells.
Expert Rev. Neurother. 2009, 9, 1447–1449. [CrossRef] [PubMed]
Cancers 2016, 8, 42 19 of 28
82. Dahan, P.; Martinez Gala, J.; Delmas, C.; Monferran, S.; Malric, L.; Zentkowski, D.; Lubrano, V.; Toulas, C.;
Cohen-Jonathan Moyal, E.; Lemarie, A. Ionizing radiations sustain glioblastoma cell dedifferentiation to
a stem-like phenotype through survivin: Possible involvement in radioresistance. Cell Death Dis. 2014.
[CrossRef] [PubMed]
83. Auffinger, B.; Tobias, A.L.; Han, Y.; Lee, G.; Guo, D.; Dey, M.; Lesniak, M.S.; Ahmed, A.U. Conversion of
differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
Cell Death Differ. 2014, 21, 1119–1131. [CrossRef] [PubMed]
84. Pawlik, T.M.; Keyomarsi, K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol.
Biol. Phys. 2004, 59, 928–942. [CrossRef] [PubMed]
85. Moore, N.; Lyle, S. Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and
discussion of significance. J. Oncol. 2011. [CrossRef] [PubMed]
86. Campos, B.; Gal, Z.; Baader, A.; Schneider, T.; Sliwinski, C.; Gassel, K.; Bageritz, J.; Grabe, N.;
von Deimling, A.; Beckhove, P.; et al. Aberrant self-renewal and quiescence contribute to the aggressiveness
of glioblastoma. J. Pathol. 2014, 234, 23–33. [CrossRef] [PubMed]
87. Goldstein, M.; Kastan, M.B. The DNA damage response: Implications for tumor responses to radiation and
chemotherapy. Annu. Rev. Med. 2015, 66, 129–143. [CrossRef] [PubMed]
88. Smith, J.; Tho, L.M.; Xu, N.; Gillespie, D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage
signaling and cancer. Adv. Cancer Res. 2010, 108, 73–112. [PubMed]
89. Bartkova, J.; Hamerlik, P.; Stockhausen, M.T.; Ehrmann, J.; Hlobilkova, A.; Laursen, H.; Kalita, O.; Kolar, Z.;
Poulsen, H.S.; Broholm, H.; et al. Replication stress and oxidative damage contribute to aberrant constitutive
activation of DNA damage signalling in human gliomas. Oncogene 2010, 29, 5095–5102. [CrossRef] [PubMed]
90. Carruthers, R.; Ahmed, S.U.; Strathdee, K.; Gomez-Roman, N.; Amoah-Buahin, E.; Watts, C.; Chalmers, A.J.
Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Mol. Oncol. 2015,
9, 192–203. [CrossRef] [PubMed]
91. Jackson, S.; Bartek, J. The DNA-damage response in human biology and disease. Nature 2009, 461, 1071–1078.
[CrossRef] [PubMed]
92. Kaelin, W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5,
689–698. [CrossRef] [PubMed]
93. Fang, B. Development of synthetic lethality anticancer therapeutics. J. Med. Chem. 2014, 57, 7859–7873.
[CrossRef] [PubMed]
94. Rouleau, M.; Patel, A.; Hendzel, M.J.; Kaufmann, S.H.; Poirier, G.G. PARP inhibition: PARP1 and beyond.
Nat. Rev. Cancer 2010, 10, 293–301. [CrossRef] [PubMed]
95. Bai, P.; Cantó, C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab.
2012, 16, 290–295. [CrossRef] [PubMed]
96. Clarke, M.J.; Mulligan, E.A.; Grogan, P.T.; Mladek, A.C.; Carlson, B.L.; Schroeder, M.A.; Curtin, N.J.; Lou, Z.;
Decker, P.A.; Wu, W.; et al. Effective sensitization of temozolomide by ABT-888 is lost with development
of temozolomide resistance in glioblastoma xenograft lines. Mol. Cancer Ther. 2009, 8, 407–414. [CrossRef]
[PubMed]
97. Barazzuol, L.; Jena, R.; Burnet, N.G.; Meira, L.B.; Jeynes, J.C.G.; Kirkby, K.J.; Kirkby, N.F. Evaluation of poly
(ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Radiat. Oncol. 2013, 8, 65–75. [CrossRef] [PubMed]
98. Donawho, C.K.; Luo, Y.; Luo, Y.; Penning, T.D.; Bauch, J.L.; Bouska, J.J.; Bontcheva-Diaz, V.D.; Cox, B.F.;
DeWeese, T.L.; Dillehay, L.E.; et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that
potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 2007, 13, 2728–2737.
[CrossRef] [PubMed]
99. Atkins, R.J.; Ng, W.; Stylli, S.S.; Hovens, C.M.; Kaye, A.H. Repair mechanisms help glioblastoma resist
treatment. J. Clin. Neurosci. 2015, 22, 14–20. [CrossRef] [PubMed]
100. Ahmed, S.U.; Carruthers, R.; Gilmour, L.; Yildirim, S.; Watts, C.; Chalmers, A.J. Selective inhibition of parallel
DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Res.
2015, 5749, 4416–4428. [CrossRef] [PubMed]
101. Cheng, L.; Wu, Q.; Huang, Z.; Guryanova, O.A.; Huang, Q.; Shou, W.; Rich, J.N.; Bao, S. L1CAM regulates
DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 2011, 30, 800–813.
[CrossRef] [PubMed]
Cancers 2016, 8, 42 20 of 28
102. Gross, E.A.; Callow, M.G.; Waldbaum, L.; Thomas, S.; Ruggieri, R. MRK, a mixed lineage kinase-related
molecule that plays a role in gamma-radiation-induced cell cycle arrest. J. Biol. Chem. 2002, 277, 13873–13882.
[CrossRef] [PubMed]
103. Tosti, E.; Waldbaum, L.; Warshaw, G.; Gross, E.A.; Ruggieri, R. The stress kinase MRK contributes to
regulation of DNA damage checkpoints through a p38γ-independent pathway. J. Biol. Chem. 2004, 279,
47652–47660. [CrossRef] [PubMed]
104. Vanan, I.; Dong, Z.; Tosti, E.; Warshaw, G.; Symons, M.; Ruggieri, R. Role of a DNA Damage Checkpoint
Pathway in Ionizing Radiation-Induced Glioblastoma Cell Migration and Invasion. Cell. Mol. Neurobiol.
2012, 32, 1199–1208. [CrossRef] [PubMed]
105. Ruggieri, R.; The Feinstein Institute, Manhasset, NY, USA. Unpublished data. 2016.
106. D’Avenia, P.; Porrello, A.; Berardo, M.; Angelo, M.D.; Soddu, S.; Arcangeli, G.; Sacchi, A.; D’Orazi, G.
Tp53-gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: A strategy to
convert a radio-resistant phenotype into a radiosensitive one. Cancer Lett. 2006, 231, 102–112. [CrossRef]
[PubMed]
107. Halliday, J.; Helmy, K.; Pattwell, S.S.; Pitter, K.L.; LaPlant, Q.; Ozawa, T.; Holland, E.C. In vivo
radiation response of proneural glioma characterized by protective p53 transcriptional program and
proneural-mesenchymal shift. Proc. Natl. Acad. Sci. USA 2014, 111, 5248–5253. [CrossRef] [PubMed]
108. Biddlestone-Thorpe, L.; Sajjad, M.; Rosenberg, E.; Beckta, J.M.; Valerie, N.C.K.; Tokarz, M.; Adams, B.R.;
Wagner, A.F.; Khalil, A.; Gilfor, D.; et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma
to ionizing radiation. Clin. Cancer Res. 2013, 19, 3189–3200. [CrossRef] [PubMed]
109. Do, K.; Doroshow, J.H.; Kummar, S. Wee1 kinase as a target for cancer therapy. Cell Cycle 2013, 12, 3159–3164.
[CrossRef] [PubMed]
110. Harvey, S.L.; Charlet, A.; Haas, W.; Gygi, S.P.; Kellogg, D.R. CDK1-dependent regulation of the mitotic
inhibitor Wee1. Cell 2005, 122, 407–420. [CrossRef] [PubMed]
111. Mir, S.E.; de Witt Hamer, P.C.; Krawczyk, P.M.; Balaj, L.; Niers, J.M.; van Tilborg, A.A.; Zwinderman, A.H.;
Geerts, D.; Kaspers, G.J.; Peter Vandertop, W.; et al. In Silico analysis of kinase expression identifies WEE1 as
a gatekeeper against mitotic catastrophe in glioblastoma shahryar. Cancer Cell 2011, 18, 244–257. [CrossRef]
[PubMed]
112. Caretti, V.; Hiddingh, L.; Lagerweij, T.; Schellen, P.; Koken, P.W.; Hulleman, E.; van Vuurden, D.G.;
Vandertop, W.P.; Kaspers, G.J.L.; Noske, D.P.; et al. WEE1 kinase inhibition enhances the radiation response
of diffuse intrinsic pontine gliomas. Mol. Cancer Ther. 2013, 12, 141–150. [CrossRef] [PubMed]
113. Chakravarti, A. Editorial on “targeting Wee1 for the treatment of pediatric high-grade gliomas”.
Neuro. Oncol. 2014. [CrossRef] [PubMed]
114. Sarcar, B.; Kahali, S.; Prabhu, A.H.; Shumway, S.D.; Xu, Y.; Demuth, T.; Chinnaiyan, P. Targeting
Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell
Lines. Mol. Cancer Ther. 2011, 10, 2405–2414. [CrossRef] [PubMed]
115. Cook, J.A.; Gius, D.; Wink, D.A.; Krishna, M.C.; Russo, A.; Mitchell, J.B. Oxidative stress, redox, and the
tumor microenvironment. Semin. Radiat. Oncol. 2004, 14, 259–266. [CrossRef] [PubMed]
116. Diehn, M.; Cho, R.W.; Lobo, N.A.; Kalisky, T.; Dorie, M.J.; Kulp, A.N.; Qian, D.; Lam, J.S.; Ailles, L.E.;
Wong, M.; et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature
2009, 458, 780–783. [CrossRef] [PubMed]
117. Rodemann, H.P.; Dittmann, K.; Toulany, M. Radiation-induced EGFR-signaling and control of DNA-damage
repair. Int. J. Radiat. Biol. 2007, 83, 781–791. [CrossRef] [PubMed]
118. Kumar, A.; Fernandez-Capetillo, O.; Carrera, A.C. Carrera Nuclear phosphoinositide 3-kinase β controls
doublestrand break DNA repair. Proc. Natl. Acad. Sci. USA 2010, 107, 7491–7496. [CrossRef] [PubMed]
119. Heddleston, J.M.; Hitomi, M.; Venere, M.; Flavahan, W.A.; Yang, K.; Kim, Y.; Minhas, S.; Rich, J.N.;
Hjelmeland, A.B. Glioma stem cell maintenance: The role of the microenvironment. Curr. Pharm. Des.
2011, 17, 2386–2401. [CrossRef] [PubMed]
120. Hardee, M.E.; Marciscano, A.E.; Medina-Ramirez, C.M.; Zagzag, D.; Narayana, A.; Lonning, S.M.;
Barcellos-Hoff, M.H. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor
microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res. 2012,
72, 4119–4129. [CrossRef] [PubMed]
Cancers 2016, 8, 42 21 of 28
121. Zhang, M.; Kleber, S.; Röhrich, M.; Timke, C.; Han, N.; Tuettenberg, J.; Martin-Villalba, A.; Debus, J.;
Peschke, P.; Wirkner, U.; et al. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761
enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 2011, 71, 7155–7167.
[CrossRef] [PubMed]
122. Miller, I.S.; Didier, S.; Murray, D.W.; Turner, T.H.; Issaivanan, M.; Ruggieri, R.; Al-Abed, Y.; Symons, M.
Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia. PLoS ONE 2014, 9,
e95885. [CrossRef] [PubMed]
123. Knisely, J.P.; Rockwell, S. Importance of hypoxia in the biology and treatment of brain tumors.
Neuroimaging Clin. N. Am. 2002, 12, 525–536. [CrossRef]
124. Fulton, D.S.; Urtasun, R.C.; Shin, K.H.; Geggie, P.H.; Thomas, H.; Muller, P.J.; Moody, J.; Tanasichuk, H.;
Mielke, B.; Johnson, E. Misonidazole combined with hyperfractionation in the management of malignant
glioma. Int. J. Radiat. Oncol. Biol. Phys. 1984, 10, 1709–1712. [CrossRef]
125. Collingridge, D.R.; Piepmeier, J.M.; Rockwell, S.; Knisely, J.P. Polarographic measurements of oxygen tension
in human glioma and surrounding peritumoural brain tissue. Radiother. Oncol. 1999, 53, 127–131. [CrossRef]
126. Yasui, H.; Asanuma, T.; Kino, J.; Yamamori, T.; Meike, S.; Nagane, M.; Kubota, N.; Kuwabara, M.; Inanami, O.
The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with
blood brain barrier disruption. BMC Cancer 2013. [CrossRef] [PubMed]
127. Kohshi, K.; Beppu, T.; Tanaka, K.; Ogawa, K.; Inoue, O.; Kukita, I.; Clarke, R.E. Potential roles of hyperbaric
oxygenation in the treatments of brain tumors. Undersea Hyperb. Med. 2013, 40, 351–362. [PubMed]
128. Dowling, S.; Fischer, J.J.; Rockwell, S. Fluosol and hyperbaric oxygen as an adjunct to radiation therapy in
the treatment of malignant gliomas: A pilot study. Biomater. Artif. Cells Immobilization Biotechnol. 1992, 20,
903–905. [CrossRef] [PubMed]
129. Overgaard, J. Hypoxic radiosensitization: Adored and ignored. J. Clin. Oncol. 2007, 25, 4066–4074. [CrossRef]
[PubMed]
130. Halperin, E.C.; Herndon, J.; Schold, S.C.; Brown, M.; Vick, N.; Cairncross, J.G.; Macdonald, D.R.; Gaspar, L.;
Fischer, B.; Dropcho, E.; et al. A phase III randomized prospective trial of external beam radiotherapy,
mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the
brain. CNS Cancer Consortium. Int. J. Radiat. Oncol. Biol. Phys. 1996, 34, 793–802. [CrossRef]
131. Del Rowe, J.; Scott, C.; Werner-Wasik, M.; Bahary, J.P.; Curran, W.J.; Urtasun, R.C.; Fisher, B. Single-arm,
open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma
multiforme. J. Clin. Oncol. 2000, 18, 1254–1259. [PubMed]
132. Womeldorff, M.; Gillespie, D.; Jensen, R.L. Hypoxia-inducible factor-1 and associated upstream and
downstream proteins in the pathophysiology and management of glioblastoma. Neurosurg. Focus 2014.
[CrossRef]
133. Heddleston, J.M.; Wu, Q.; Rivera, M.; Minhas, S.; Lathia, J.D.; Sloan, A.E.; Iliopoulos, O.; Hjelmeland, A.B.;
Rich, J.N. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential.
Cell Death Differ. 2012, 19, 428–439. [CrossRef] [PubMed]
134. Kopan, R.; Ilagan, M.X.G. The canonical notch signaling pathway: Unfolding the activation mechanism. Cell
2009, 137, 216–233. [CrossRef] [PubMed]
135. Mizutani, K.; Yoon, K.; Dang, L.; Tokunaga, A.; Gaiano, N. Differential Notch signalling distinguishes neural
stem cells from intermediate progenitors. Nature 2007, 449, 351–355. [CrossRef] [PubMed]
136. Louvi, A.; Artavanis-Tsakonas, S. Notch signalling in vertebrate neural development. Nat. Rev. Neurosci.
2006, 7, 93–102. [CrossRef] [PubMed]
137. Fan, X.; Matsui, W.; Khaki, L.; Stearns, D.; Chun, J.; Li, Y.M.; Eberhart, C.G. Notch pathway inhibition
depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006, 66, 7445–7452.
[CrossRef] [PubMed]
138. Teodorczyk, M.; Schmidt, M.H. Notching on cancer’s door: Notch signaling in brain tumors.
Front. Oncol. 2014. [CrossRef]
139. Chen, J.; Kesari, S.; Rooney, C.; Strack, P.R.; Chen, J.; Shen, H.; Wu, L.; Griffin, J.D. Inhibition of notch
signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 2010, 1, 822–835.
[CrossRef] [PubMed]
Cancers 2016, 8, 42 22 of 28
140. Brennan, C.; Momota, H.; Hambardzumyan, D.; Ozawa, T.; Tandon, A.; Pedraza, A.; Holland, E. Glioblastoma
subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.
PLoS ONE 2009, 4, 1–10. [CrossRef] [PubMed]
141. Brennan, C. Genomic profiles of glioma. Curr. Neurol. Neurosci. Rep. 2011, 11, 291–297. [CrossRef] [PubMed]
142. Kim, E.J.; Kim, S.O.; Jin, X.; Ham, S.W.; Kim, J.; Park, J.B.; Lee, J.Y.; Kim, S.C.; Kim, H. Epidermal growth
factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1. Tumor Biol. 2014, 36,
2921–2928. [CrossRef] [PubMed]
143. Saito, N.; Fu, J.; Zheng, S.; Yao, J.; Wang, S.; Liu, D.D.; Yuan, Y.; Sulman, E.P.; Lang, F.F.; Colman, H.; et al.
A high notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma
tumor-initiating cells. Stem Cells 2014, 32, 301–312. [CrossRef] [PubMed]
144. Wang, J.; Wakeman, T.P.; Latha, J.D.; Hjelmeland, A.B.; White, R.R.; Rich, J.N.; Sullenger, B. A notch promotes
radioresistance of glioma stem cells. Stem Cells 2011, 28, 17–28. [CrossRef] [PubMed]
145. Clevers, H. Wnt/Beta-catenin signaling in development and disease. Cell 2006, 127, 469–480. [CrossRef]
[PubMed]
146. Grigoryan, T.; Wend, P.; Klaus, A.; Birchmeier, W. Deciphering the function of canonical Wnt signals
in development and disease: Conditional loss- and gain-of-function mutations of beta-catenin in mice.
Genes Dev. 2008, 22, 2308–2341. [CrossRef] [PubMed]
147. Kim, Y.; Kim, K.H.; Lee, H.; Yang, H.; Kim, D.; Kang, W.; Jin, J.; Joo, K.M.; Lee, J.; Nam, D.-H. Wnt activation
is implicated in glioblastoma radioresistance. Lab. Investig. 2012, 92, 466–473. [CrossRef] [PubMed]
148. Zheng, H.; Ying, H.; Wiedemeyer, R.; Yan, H.; Quayle, S.N.; Ivanova, E.V.; Paik, J.H.; Zhang, H.; Xiao, Y.;
Perry, S.R.; et al. PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and
Gliomas. Cancer Cell 2010, 17, 497–509. [CrossRef] [PubMed]
149. Roth, W.; Wild-Bode, C.; Platten, M.; Grimmel, C.; Melkonyan, H.S.; Dichgans, J.; Weller, M. Secreted
Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene
2000, 19, 4210–4220. [CrossRef] [PubMed]
150. Götze, S.; Wolter, M.; Reifenberger, G.; Müller, O.; Sievers, S. Frequent promoter hypermethylation of Wnt
pathway inhibitor genes in malignant astrocytic gliomas. Int. J. Cancer 2010, 126, 2584–2593. [PubMed]
151. Rheinbay, E.; Suvà, M.L.; Gillespie, S.M.; Wakimoto, H.; Patel, A.P.; Shahid, M.; Oksuz, O.; Rabkin, S.D.;
Martuza, R.L.; Rivera, M.N.; et al. An aberrant transcription factor network essential for Wnt signaling and
stem cell maintenance in glioblastoma. Cell Rep. 2013, 3, 1567–1579. [CrossRef] [PubMed]
152. Guo, G.; Mao, X.; Wang, P.; Liu, B.; Zhang, X.; Jiang, X.; Zhong, C.; Huo, J.; Jin, J.; Zhuo, Y. The expression
profile of FRAT1 in human gliomas. Brain Res. 2010, 1320, 152–158. [CrossRef] [PubMed]
153. Guo, G.; Kuai, D.; Cai, S.; Xue, N.; Liu, Y.; Hao, J.; Fan, Y.; Jin, J.; Mao, X.; Liu, B.; et al. Knockdown of
FRAT1 Expression by RNA Interference Inhibits Human Glioblastoma Cell Growth, Migration and Invasion.
PLoS ONE 2013. [CrossRef] [PubMed]
154. Wang, Z.X.; Chen, Y.Y.; Li, B.A.; Tan, G.W.; Liu, X.Y.; Shen, S.H.; Zhu, H.W.; Wang, H.D. Decreased pygopus
2 expression suppresses glioblastoma U251 cell growth. J. Neurooncol. 2010, 100, 31–41. [CrossRef] [PubMed]
155. Lin, D.C.; Xu, L.; Chen, Y.; Yan, H.; Hazawa, M.; Doan, N.; Said, J.W.; Ding, L.W.; Liu, L.Z.; Yang, H.; et al.
Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma. Cancer Res. 2015, 75, 1815–1828.
[CrossRef] [PubMed]
156. Northcott, P.A.; Korshunov, A.; Witt, H.; Hielscher, T.; Eberhart, C.G.; Mack, S.; Bouffet, E.; Clifford, S.C.;
Hawkins, C.E.; French, P.; et al. Medulloblastoma Comprises Four Distinct Molecular Variants. J. Clin. Oncol.
2011, 29, 1408–1414. [CrossRef] [PubMed]
157. Salaroli, R.; Ronchi, A.; Buttarelli, F.R.; Cortesi, F.; Marchese, V.; Della Bella, E.; Renna, C.; Baldi, C.;
Giangaspero, F.; Cenacchi, G. Wnt activation affects proliferation, invasiveness and radiosensitivity in
medulloblastoma. J. Neurooncol. 2015, 121, 119–127. [CrossRef] [PubMed]
158. Traiffort, E.; Angot, E.; Ruat, M. Sonic Hedgehog signaling in the mammalian brain. J. Neurochem. 2010, 113,
576–590. [CrossRef] [PubMed]
159. Shahi, M.H.; Rey, J.A.; Castresana, J.S. The sonic hedgehog-GLI1 signaling pathway in brain tumor
development. Expert Opin. Ther. Targets 2012, 12, 1227–1238. [CrossRef] [PubMed]
160. Ruiz i Altaba, A.; Palma, V.; Dahmane, N. Hedgehog-Gli signalling and the growth of the brain.
Nat. Rev. Neurosci. 2002, 3, 24–33. [CrossRef] [PubMed]
Cancers 2016, 8, 42 23 of 28
161. Santoni, M.; Burattini, L.; Nabissi, M.; Morelli, M.B.; Berardi, R.; Santoni, G.; Cascinu, S. Essential role of Gli
proteins in glioblastoma multiforme. Curr. Protein Pept. Sci. 2013, 14, 133–140. [CrossRef] [PubMed]
162. Hsieh, A.; Ellsworth, R.; Hsieh, D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma
stem cells. J. Cell. Physiol. 2011, 226, 1118–1127. [CrossRef] [PubMed]
163. Shahi, M.H.; Lorente, A.; Castresana, J.S. Hedgehog signalling in medulloblastoma, glioblastoma and
neuroblastoma. Oncol. Rep. 2008, 19, 681–688. [CrossRef] [PubMed]
164. Michael, L.E.; Westerman, B.A.; Ermilov, A.; Wang, A.; Ferris, J.; Liu, J.; Blom, M.; Ellison, D.;
van Lohuizen, M.; Dlugosz, A. Bmi1 Is Required for Hedgehog Pathway—-Driven medulloblastome
expansion. Neoplasia 2008, 10, 1343–1349. [CrossRef] [PubMed]
165. Wang, X.; Venugopal, C.; Manoranjan, B.; McFarlane, N.; O’Farrell, E.; Nolte, S.; Gunnarsson, T.;
Hollenberg, R.; Kwiecien, J.; Northcott, P.; et al. Sonic hedgehog regulates Bmi1 in human medulloblastoma
brain tumor-initiating cells. Oncogene 2012, 31, 187–199. [CrossRef] [PubMed]
166. Zencak, D.; Lingbeek, M.; Kostic, C.; Tekaya, M.; Tanger, E.; Hornfeld, D.; Jaquet, M.; Munier, F.L.;
Schorderet, D.F.; van Lohuizen, M.; et al. Bmi1 loss produces an increase in astroglial cells and a decrease in
neural stem cell population and proliferation. J. Neurosci. 2005, 25, 5774–5783. [CrossRef] [PubMed]
167. Leung, C.; Lingbeek, M.; Shakhova, O.; Liu, J.; Tanger, E.; Saremaslani, P.; van Lohuizen, M.; Marino, S. Bmi1
is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004, 428,
337–341. [CrossRef] [PubMed]
168. Abdouh, M.; Facchino, S.; Chatoo, W.; Balasingam, V.; Ferreira, J.; Bernier, G. BMI1 sustains human
glioblastoma multiforme stem cell renewal. J. Neurosci. 2009, 29, 8884–8896. [CrossRef] [PubMed]
169. Liu, J.; Cao, L.; Chen, J.; Song, S.; Lee, I.H.; Quijano, C.; Liu, H.; Keyvanfar, K.; Chen, H.; Cao, L.Y.; et al.
Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 2009, 459, 387–392.
[CrossRef] [PubMed]
170. Ismail, H.; Andrin, C.; McDonald, D.; Hendzel, M.J. BMI1-mediated histone ubiquitylation promotes DNA
double-strand break repair. J. Cell Biol. 2010, 191, 45–60. [CrossRef] [PubMed]
171. Berman, D.M.; Karhadkar, S.S.; Hallahan, A.R.; Pritchard, J.I.; Eberhart, C.G.; Watkins, D.N.; Chen, J.K.;
Cooper, M.K.; Taipale, J.; Olson, J.M.; et al. Medulloblastoma growth inhibition by hedgehog pathway
blockade. Science 2002, 297, 1559–1561. [CrossRef] [PubMed]
172. Bar, E.E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A.L.; DiMeco, F.;
Olivi, A.; et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in
glioblastoma. Stem Cells 2007, 25, 2524–2533. [CrossRef] [PubMed]
173. Rudin, C.M.; Hann, C.L.; Laterra, J.; Yauch, R.L.; Callahan, C.A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S.E.;
Coleman, B.; et al. A treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl.
J. Med. 2009, 361, 1173–1178. [CrossRef] [PubMed]
174. Amakye, D.; Jagani, Z.; Dorsch, M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer.
Nat. Med. 2013, 19, 1410–1422. [CrossRef] [PubMed]
175. Haley, E.M.; Kim, Y. The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma
stem cells and in their in vitro culture. Cancer Lett. 2014, 346, 1–5. [CrossRef] [PubMed]
176. Lee, J.; Kotliarova, S.; Kotliarov, Y.; Li, A.; Su, Q.; Donin, N.M.; Pastorino, S.; Purow, B.W.; Christopher, N.;
Zhang, W.; et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely
mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9,
391–403. [CrossRef] [PubMed]
177. Pollard, S.M.; Yoshikawa, K.; Clarke, I.D.; Danovi, D.; Stricker, S.; Russell, R.; Bayani, J.; Head, R.; Lee, M.;
Bernstein, M.; et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes
and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4, 568–580. [CrossRef] [PubMed]
178. Lathia, J.D.; Hitomi, M.; Gallagher, J.; Gadani, S.P.; Adkins, J.; Vasanji, A.; Liu, L.; Eyler, C.E.; Heddleston, J.M.;
Wu, Q.; et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric
cell divisions. Cell Death Dis. 2011. [CrossRef] [PubMed]
179. Fuks, Z.; Persaud, R.S.; Alfieri, A.; McLoughlin, M.; Ehleiter, D.; Schwartz, J.L.; Seddon, A.P.;
Cordon-Cardo, C.; Haimovitz-Friedman, A. Basic fibroblast growth factor protects endothelial cells against
radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 1994, 54, 2582–2590. [PubMed]
Cancers 2016, 8, 42 24 of 28
180. Haimovitz-Friedman, A.; Balaban, N.; McLoughlin, M.; Ehleiter, D.; Michaeli, J.; Vlodavsky, I.;
Fuks, Z. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against
radiation-induced apoptosis. Cancer Res. 1994, 54, 2591–2597. [PubMed]
181. Ader, I.; Toulas, C.; Dalenc, F.; Delmas, C.; Bonnet, J.; Cohen-Jonathan, E.; Favre, G. RhoB controls the 24
kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 2002, 21,
5998–6006. [CrossRef] [PubMed]
182. Delmas, C.; Heliez, C.; Cohen-Jonathan, E.; End, D.; Bonnet, J.; Favre, G.; Toulas, C. Farnesyltransferase
inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int. J. Cancer 2002,
100, 43–48. [CrossRef] [PubMed]
183. Srougi, M.C.; Burridge, K. The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate
RhoB-mediated cell death after DNA damage. PLoS ONE 2011. [CrossRef] [PubMed]
184. Monferran, S.; Skuli, N.; Delmas, C.; Favre, G.; Bonnet, J.; Cohen-Jonathan-Moyal, E.; Toulas, C. AlphavBeta3
and AlphavBeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
Int. J. Cancer 2008, 123, 357–364. [CrossRef] [PubMed]
185. Mamouni, K.; Cristini, A.; Guirouilh-Barbat, J.; Monferran, S.; Lemarie, A.; Faye, J.C.; Lopez, B.S.;
Favre, G.; Sordet, O. RhoB promotes gammaH2AX dephosphorylation and DNA double-strand break
repair. Mol. Cell Biol. 2014, 34, 3144–3155. [CrossRef] [PubMed]
186. Ducassou, A.; Uro-Coste, E.; Verrelle, P.; Filleron, T.; Benouaich-Amiel, A.; Lubrano, V.; Sol, J.C.; Delisle, M.B.;
Favre, G.; Ken, S.; et al. αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in
a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients
with newly diagnosed glioblastoma. Eur. J. Cancer 2013, 49, 2161–2169. [CrossRef] [PubMed]
187. Ader, I.; Delmas, C.; Skuli, N.; Bonnet, J.; Schaeffer, P.; Bono, F.; Cohen-Jonathan-Moyal, E.; Toulas, C.
Preclinical evidence that SSR128129E—-A novel small-molecule multi-fibroblast growth factor receptor
blocker—-Radiosensitises human glioblastoma. Eur. J. Cancer 2014, 50, 2351–2359. [CrossRef] [PubMed]
188. Burrows, R.C.; Wancio, D.; Levitt, P.; Lillien, L. Response diversity and the timing of progenitor cell
maturation are regulated by developmental changes in EGFR expression in the cortex. Neuron 1997, 19,
251–267. [CrossRef]
189. Chakravarti, A.; Dicker, A.; Mehta, M. The contribution of epidermal growth factor receptor (EGFR) signaling
pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data. Int. J.
Radiat. Oncol. Biol. Phys. 2004, 58, 927–931. [CrossRef] [PubMed]
190. Wong, A.J.; Bigner, S.H.; Bigner, D.D.; Kinzler, K.W.; Hamilton, S.R.; Vogelstein, B. Increased expression of the
epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.
Proc. Natl. Acad. Sci. USA 1987, 84, 6899–6903. [CrossRef] [PubMed]
191. Wong, A.J.; Ruppert, J.M.; Bigner, S.H.; Grzeschik, C.H.; Humphrey, P.A.; Bigner, D.S.; Vogelstein, B.
Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad.
Sci. USA 1992, 89, 2965–2969. [CrossRef] [PubMed]
192. Humphrey, P.A.; Wong, A.J.; Vogelstein, B.; Zalutsky, M.R.; Fuller, G.N.; Archer, G.E.; Friedman, H.S.;
Kwatra, M.M.; Bigner, S.H.; Bigner, D.D. Anti-synthetic peptide antibody reacting at the fusion junction of
deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. USA 1990,
87, 4207–4211. [CrossRef] [PubMed]
193. Gan, H.K.; Kaye, A.H.; Luwor, R.B. The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 2009,
16, 748–754. [CrossRef] [PubMed]
194. Chakravarti, A.; Chakladar, A.; Delaney, M.A.; Latham, D.E.; Loeffler, J.S. The epidermal growth factor
receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary
human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002, 62, 4307–4315. [PubMed]
195. Lammering, G.; Hewit, T.H.; Hawkins, W.T.; Contessa, J.N.; Reardon, D.B.; Lin, P.S.; Valerie, K.; Dent, P.;
Mikkelsen, R.B.; Schmidt-Ullrich, R.K. Epidermal growth factor receptor as a genetic therapy target for
carcinoma cell radiosensitization. J. Natl. Cancer Inst. 2004, 279, 15130–15141. [CrossRef]
196. Lammering, G.; Lin, P.S.; Contessa, J.N.; Hampton, J.L.; Valerie, K.; Schmidt-Ullrich, R.K.
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as
a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int. J. Radiat.
Oncol. Biol. Phys. 2001, 51, 775–784. [CrossRef]
Cancers 2016, 8, 42 25 of 28
197. Lammering, G.; Valerie, K.; Lin, P.S.; Mikkelsen, R.B.; Contessa, J.N.; Feden, J.P.; Farnsworth, J.;
Dent, P.; Schmidt-Ullrich, R.K. Radiosensitization of malignant glioma cells through overexpression of
dominant-negative epidermal growth factor receptor. Clin. Cancer Res. 2001, 7, 682–690. [PubMed]
198. Li, L.; Quang, T.S.; Gracely, E.J.; Kim, J.H.; Emrich, J.G.; Yaeger, T.E.; Jenrette, J.M.; Cohen, S.C.; Black, P.;
Brady, L.W. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment
of glioblastoma multiforme. J. Neurosurg. 2010, 113, 192–198. [CrossRef] [PubMed]
199. Padfield, E.; Ellis, H.P.; Kurian, K.M. Current therapeutic advances targeting EGFR and EGFRvIII in
glioblastoma. Front. Oncol. 2015, 5, 1–8. [CrossRef] [PubMed]
200. Liffers, K.; Lamszus, K.; Schulte, A. EGFR amplification and glioblastoma stem-like cells. Stem Cells Int. 2015,
2015, 427518–427529. [CrossRef] [PubMed]
201. Osuka, S.; Sampetrean, O.; Shimizu, T.; Saga, I.; Onishi, N.; Sugihara, E.; Okubo, J.; Fujita, S.; Takano, S.;
Matsumura, A.; et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells.
Stem Cells 2013, 31, 627–640. [CrossRef] [PubMed]
202. Achim, C.L.; Katyal, S.; Wiley, C.A.; Shiratori, M.; Wang, G.; Oshika, E.; Petersen, B.E.; Li, J.M.;
Michalopoulos, G.K. Expression of HGF and cMET in the developing and adult brain. Dev. Brain Res.
1997, 102, 299–303. [CrossRef]
203. Koochekpour, S.; Jeffers, M.; Rulong, S.; Taylor, G.; Klineberg, E.; Hudson, E.A.; Resau, J.H.; vande
Woude, G.F. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997,
57, 5391–5398. [PubMed]
204. Moriyama, T.; Kataoka, H.; Koono, M.; Wakisaka, S. Expression of hepatocyte growth factor/scatter factor
and its receptor c-Met in brain tumors: Evidence for a role in progression of astrocytic tumors. Int. J.
Mol. Med. 1999, 3, 531–536. [CrossRef] [PubMed]
205. Bowers, D.C.; Fan, S.; Walter, K.A.; Abounader, R.; Williams, J.A.; Rosen, E.M.; Laterra, J.
Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via
phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res. 2000, 60, 4277–4283. [PubMed]
206. Abounader, R.; Laterra, J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.
Neuro-oncology 2005, 7, 436–451. [CrossRef] [PubMed]
207. Lal, B.; Xia, S.; Abounader, R.; Laterra, J. Targeting the c-Met pathway potentiates glioblastoma responses to
γ-radiation. Clin. Cancer Res. 2005, 11, 4479–4486. [CrossRef] [PubMed]
208. Matheny, R.W., Jr.; Adamo, M.L. Current perspectives on Akt Akt-ivation and Akt-ions. Exp. Biol.
Med. (Maywood). 2009, 234, 1264–1270. [CrossRef] [PubMed]
209. Manning, B.D.; Cantley, L.C. AKT/PKB Signaling: Navigating downstream. Cell 2007, 129, 1261–1274.
[CrossRef] [PubMed]
210. Chakravarti, A. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human
gliomas. J. Clin. Oncol. 2004, 22, 1926–1933. [CrossRef] [PubMed]
211. Phillips, H.S.; Kharbanda, S.; Chen, R.; Forrest, W.F.; Soriano, R.H.; Wu, T.D.; Misra, A.; Nigro, J.M.;
Colman, H.; Soroceanu, L.; et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a
pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9, 157–173. [CrossRef]
[PubMed]
212. Matsutani, T.; Nagai, Y.; Mine, S.; Murai, H.; Saeki, N.; Iwadate, Y. Akt/protein kinase B overexpression
as an accurate prognostic marker in adult diffuse astrocytoma. Acta Neurochir. (Wien). 2009, 151, 263–268.
[CrossRef] [PubMed]
213. Zheng, H.; Ying, H.; Yan, H.; Kimmelman, A.C.; Hiller, D.J.; Chen, A.J.; Perry, S.R.; Tonon, G.; Chu, G.C.;
Ding, Z.; et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
Nature 2008, 455, 1129–1133. [CrossRef] [PubMed]
214. McDowell, K.A.; Riggins, G.J.; Gallia, G.L. Targeting the AKT pathway in glioblastoma. Curr. Pharm. Des.
2011, 17, 2411–2420. [CrossRef] [PubMed]
215. Knobbe, C.B.; Trampe-Kieslich, A.; Reifenberger, G. Genetic alteration and expression of the
phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas.
Neuropathol. Appl. Neurobiol. 2005, 31, 486–490. [CrossRef] [PubMed]
216. Knobbe, C.B.; Reifenberger, J.; Blaschke, B.; Reifenberger, G. Hypermethylation and transcriptional
downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J. Natl. Cancer Inst. 2004,
96, 483–486. [CrossRef] [PubMed]
Cancers 2016, 8, 42 26 of 28
217. Hambardzumyan, D.; Squatrito, M.; Carbajal, E.; Holland, E.C. Glioma formation, cancer stem cells, and Akt
signaling. Stem Cell Rev. 2008, 4, 203–210. [CrossRef] [PubMed]
218. Gallia, G.L.; Tyler, B.M.; Hann, C.L.; Siu, I.M.; Giranda, V.L.; Vescovi, A.L.; Brem, H.; Riggins, G.J. Inhibition
of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol. Cancer Ther. 2009, 8, 386–393.
[CrossRef] [PubMed]
219. Eyler, C.E.; Foo, W.; Lafiura, K.M.; Mclendon, R.E.; Hjelmeland, A.B.; Rich, J.N. Brain cancer stem cells
display preferential sensitivity to Akt inhibition. Stem Cells 2009, 26, 3027–3036. [CrossRef] [PubMed]
220. Włodarski, P.; Grajkowska, W.; Łojek, M.; Rainko, K.; Józ´wiak, J. Activation of Akt and Erk pathways in
medulloblastoma. Folia Neuropathol. 2006, 44, 214–220. [PubMed]
221. Kao, G.D.; Jiang, Z.; Fernandes, A.M.; Gupta, A.K.; Maity, A. Inhibition of phosphatidylinositol-3-OH
kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J. Biol. Chem.
2007, 282, 21206–21212. [CrossRef] [PubMed]
222. Li, H.F.; Kim, J.S.; Waldman, T. Radiation-induced Akt activation modulates radioresistance in human
glioblastoma cells. Radiat. Oncol. 2009, 4, 43–52. [CrossRef] [PubMed]
223. Mehta, M.; Khan, A.; Danish, S.; Haffty, B.G.; Sabaawy, H.E. Radiosensitization of primary human
glioblastoma stem-like cells with low-dose AKT Inhibition. Mol. Cancer Ther. 2015, 14, 1171–1181. [CrossRef]
[PubMed]
224. Laplante, M.; Sabatini, D.M. mTOR signaling at a glance. J. Cell Sci. 2009, 122, 3589–3594. [CrossRef]
[PubMed]
225. Laplante, M.; Sabatini, D.M. mTOR signaling in growth control and disease. Cell 2013, 149, 274–293.
[CrossRef] [PubMed]
226. Dasgupta, T.; Haas-Kogan, D.A. The combination of novel targeted molecular agents and radiation in the
treatment of pediatric gliomas. Front. Oncol. 2013. [CrossRef] [PubMed]
227. Pópulo, H.; Lopes, J.M.; Soares, P. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 2012, 13,
1886–1918. [CrossRef] [PubMed]
228. Hambardzumyan, D.; Becher, O.J.; Rosenblum, M.K.; Pandolfi, P.P.; Manova-Todorova, K.; Holland, E.C.
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation
in medulloblastoma in vivo. Genes Dev. 2008, 22, 436–448. [CrossRef] [PubMed]
229. Zhuang, W.; Qin, Z.; Liang, Z. The role of autophagy in sensitizing malignant glioma cells to radiation
therapy. Acta Biochim. Biophys. Sin. 2009, 41, 341–351. [CrossRef] [PubMed]
230. Maity, A.; Cerniglia, G.J.; Karar, J.; Koumenis, C. Inhibition of autophagy as a strategy to augment
radiosensitization by the dual PI3K/mTOR inhibitor NVP-BEZ235. Int. J. Radiat. Oncol. 2012, 82, 1230–1240.
[CrossRef]
231. Wang, W.; Long, L.; Yang, N.; Zhang, Q.; Ji, W.; Zhao, J.; Qin, Z.; Wang, Z.; Chen, G.; Liang, Z. NVP-BEZ235,
a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.
Acta Pharmacol. Sin. 2013, 34, 681–690. [CrossRef] [PubMed]
232. Liu, T.J.; Koul, D.; LaFortune, T.; Tiao, N.; Shen, R.J.; Maira, S.M.; Garcia-Echevrria, C.; Yung, W.K.
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits
multifaceted antitumor activities in human gliomas. Mol. Cancer Ther. 2009, 8, 2204–2210. [CrossRef]
[PubMed]
233. Lomonaco, S.L.; Finniss, S.; Xiang, C.; DeCarvalho, A.; Umansky, F.; Kalkanis, S.N.; Mikkelsen, T.; Brodie, C.
The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells.
Int. J. Cancer 2009, 125, 717–722. [CrossRef] [PubMed]
234. Nam, H.Y.; Han, M.W.; Chang, H.W.; Lee, Y.S.; Lee, M.; Lee, H.J.; Lee, B.W.; Lee, H.J.; Lee, K.E.;
Jung, M.K.; et al. Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition.
Cancer Res. 2013, 73, 4267–4277. [CrossRef] [PubMed]
235. Rouschop, K.M.; Dubois, L.; Schaaf, M.B.; van den Beucken, T.; Lieuwes, N.; Keulers, T.G.; Savelkouls, K.G.;
Bussink, J.; van der Kogel, A.J.; Koritzinsky, M.; et al. Deregulation of cap-dependent mRNA translation
increases tumour radiosensitivity through reduction of the hypoxic fraction. Radiother. Oncol. 2011, 99,
385–391. [CrossRef] [PubMed]
236. Fan, Q.W.; Weiss, W.A. Targeting the RTK-PI3K-mTOR axis in malignant glioma: Overcoming resistance.
Curr. Top. Microbiol. Immunol. 2010, 347, 279–296. [PubMed]
Cancers 2016, 8, 42 27 of 28
237. Sarkaria, J.N.; Galanis, E.; Wu, W.; Peller, P.J.; Giannini, C.; Brown, P.D.; Uhm, J.H.; McGraw, S.; Jaeckle, K.A.;
Buckner, J.C. North central cancer treatment group Phase I trial N057K of everolimus (RAD001) and
temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma
multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, 468–475. [CrossRef] [PubMed]
238. Sarkaria, J.N.; Galanis, E.; Wu, W.; Dietz, A.B.; Kaufmann, T.J.; Gustafson, M.P.; Brown, P.D.; Uhm, J.H.;
Rao, R.D.; Doyle, L.; et al. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed
glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.
Clin. Cancer Res. 2010, 16, 5573–5580. [CrossRef] [PubMed]
239. Choi, E.J.; Cho, B.J.; Lee, D.J.; Hwang, Y.H.; Chun, S.H.; Kim, H.H.; Kim, I.A. Enhanced cytotoxic effect of
radiation and temozolomide in malignant glioma cells: Targeting PI3K-AKT-mTOR signaling, HSP90 and
histone deacetylases. BMC Cancer 2014, 14, 17–28. [CrossRef] [PubMed]
240. Prasad, G.; Sottero, T.; Yang, X.; Mueller, S.; James, C.D.; Weiss, W.A.; Polley, M.Y.; Ozawa, T.; Berger, M.S.;
Aftab, D.T.; et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination
therapy with temozolomide. Neuro-oncology 2011, 13, 384–392. [CrossRef] [PubMed]
241. Gil del Alcazar, C.R.; Hardebeck, M.C.; Mukherjee, B.; Tomimatsu, N.; Gao, X.; Yan, J.; Xie, X.J.; Bachoo, R.;
Li, L.; Habib, A.A.; et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR Inhibitor
NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin. Cancer Res. 2014, 20, 1235–1248.
[CrossRef] [PubMed]
242. Palumbo, S.; Tini, P.; Toscano, M.; Allavena, G.; Angeletti, F.; Manai, F.; Miracco, C.; Comincini, S.; Pirtoli, L.
Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human
glioblastoma cells. J. Cell. Physiol. 2014, 229, 1863–1873. [CrossRef] [PubMed]
243. Gilmore, T.D. Introduction to NF-κB: Players, pathways, perspectives. Oncogene 2006, 25, 6680–6684.
[CrossRef] [PubMed]
244. Bhat, K.P.; Balasubramaniyan, V.; Vaillant, B.; Ezhilarasan, R.; Hummelink, K.; Hollingsworth, F.; Wani, K.;
Heathcock, L.; James, J.D.; Goodman, L.D.; et al. Mesenchymal differentiation mediated by NF-κB promotes
radiation resistance in glioblastoma. Cancer Cell 2013, 24, 331–346. [CrossRef] [PubMed]
245. Kim, S.H.; Ezhilarasan, R.; Phillips, E.; Gallego-Perez, D.; Sparks, A.; Taylor, D.; Ladner, K.; Furuta, T.;
Sabit, H.; Chhipa, R.; et al. Serine/Threonine kinase MLK4 determines mesenchymal identity in glioma stem
cells in an NF-kappaB-dependent manner. Cancer Cell 2016, 29, 201–213. [CrossRef] [PubMed]
246. Sinha, S.; Ghildiyal, R.; Mehta, V.S.; Sen, E. ATM-NFκB axis-driven TIGAR regulates sensitivity of glioma
cells to radiomimetics in the presence of TNFα. Cell Death Dis. 2013. [CrossRef] [PubMed]
247. Hein, A.; Ouellette, M.; Yan, Y. Radiation-induced signaling pathways that promote cancer cell survival
(Review). Int. J. Oncol. 2014, 45, 1813–1819. [CrossRef] [PubMed]
248. Xu, R.X.; Liu, R.Y.; Wu, C.M.; Zhao, Y.S.; Li, Y.; Yao, Y.Q.; Xu, Y.H. DNA damage-induced NF-κB activation
in human glioblastoma cells promotes miR-181b expression and cell proliferation. Cell. Physiol. Biochem.
2015, 35, 913–925. [CrossRef] [PubMed]
249. Séhédic, D.; Cikankowitz, A.; Hindré, F.; Davodeau, F.; Garcion, E. Nanomedicine to overcome
radioresistance in glioblastoma stem-like cells and surviving clones. Trends Pharmacol. Sci. 2015, 36,
236–252. [CrossRef] [PubMed]
250. Gill, J.S.; Zhu, X.; Moore, M.J.; Lu, L.; Yaszemski, M.J.; Windebank, A.J. Effects of NF-Kappa-B decoy
oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials
2002, 23, 2773–2781. [CrossRef]
251. Brassesco, M.S.; Roberto, G.M.; Morales, A.G.; Oliveira, J.C.; Delsin, L.E.; Pezuk, J.A.; Valera, E.T.;
Carlotti, C.G.; Rego, E.M.; de Oliveira, H.F.; et al. Inhibition of NF-κB by dehydroxymethylepoxyquinomicin
suppresses invasion and synergistically potentiates temozolomide and γ-radiation cytotoxicity in
glioblastoma cells. Chemother. Res. Pract. 2013, 2013, 1–16. [CrossRef] [PubMed]
252. Atkinson, G.P.; Nozell, S.E.; Benveniste, E.T. NF-kappaB and STAT3 signaling in glioma: Targets for future
therapies. Expert Rev. Neurother. 2010, 10, 575–586. [CrossRef] [PubMed]
253. Robe, P.A.; Martin, D.H.; Nguyen-Khac, M.T.; Artesi, M.; Deprez, M.; Albert, A.; Vanbelle, S.; Califice, S.;
Bredel, M.; Bours, V. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of
sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 2009, 9, 1471–2407.
[CrossRef] [PubMed]
Cancers 2016, 8, 42 28 of 28
254. Kanno, H.; Miyake, S.; Nakanowatari, S. Signaling pathways in glioblastoma cancer stem cells: A role of
Stat3 as a potential therapeutic target. Austin J. Cancer Clin. Res. 2015, 2, 1030–1035.
255. Bowman, T.; Garcia, R.; Turkson, J.; Jove, R. STATs in oncogenesis. Oncogene 2000, 19, 2474–2488. [CrossRef]
[PubMed]
256. Bromberg, J.F.; Wrzeszczynska, M.H.; Devgan, G.; Zhao, Y.; Pestell, R.G.; Albanese, C.; Darnell, J.E. Stat3 as
an oncogene. Cell 1999, 98, 295–303. [CrossRef]
257. Heinrich, P.C.; Behrmann, I.; Müller-Newen, G.; Schaper, F.; Graeve, L. Interleukin-6-type cytokine signalling
through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334, 297–314. [CrossRef] [PubMed]
258. Darnell, J.E.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs
and other extracellular signaling proteins. Science 1994, 264, 1415–1421. [CrossRef] [PubMed]
259. Ihle, J.N. STATs: Signal transducers and activators of transcription. Cell 1996, 84, 331–334. [CrossRef]
260. Swiatek-Machado, K.; Kaminska, B. STAT signaling in glioma cells. Adv. Exp. Med. Biol. 2013, 986, 189–208.
[PubMed]
261. Schaefer, L.K.; Ren, Z.; Fuller, G.N.; Schaefer, T.S. Constitutive activation of Stat3α in brain tumors:
Localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2).
Oncogene 2002, 21, 2058–2065. [CrossRef] [PubMed]
262. Rahaman, S.O. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: Involvement of IL-13Rα2.
Cancer Res. 2005, 65, 2956–2963. [CrossRef] [PubMed]
263. Lo, H.W.; Cao, X.; Zhu, H.; Ali-Osman, F. Constitutively activated STAT3 frequently coexpresses with
epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and
alkylators. Clin. Cancer Res. 2008, 14, 6042–6054. [CrossRef] [PubMed]
264. Cattaneo, E.; Magrassi, L.; De-Fraja, C.; Conti, L.; Di Gennaro, I.; Butti, G.; Govoni, S. Variations in the levels
of the JAK/STAT and ShcA proteins in human brain tumors. Anticancer Res. 1998, 18, 2381–2387. [PubMed]
265. Ouédraogo, Z.G.; Müller-Barthélémy, M.; Kemeny, J.L.; Dedieu, V.; Biau, J.; Khalil, T.; Raoelfils, L.I.;
Granzotto, A.; Pereira, B.; Beaudoin, C.; et al. STAT3 serine 727 phosphorylation: A relevant target to
radiosensitize human glioblastoma. Brain Pathol. 2015, 3. [CrossRef] [PubMed]
266. Lin, L.; Deangelis, S.; Foust, E.; Fuchs, J.; Li, C.; Li, P.K.; Schwartz, E.B.; Lesinski, G.B.; Benson, D.; Lü, J.; et al.
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent
growth suppressive activity in human cancer cells. Mol. Cancer 2010, 9, 217–226. [CrossRef] [PubMed]
267. Yang, Y.P.; Chang, Y.L.; Huang, P.I.; Chiou, G.Y.; Tseng, L.M.; Chiou, S.H.; Chen, M.H.; Chen, M.T.;
Shih, Y.H.; Chang, C.H.; et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in
primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J. Cell. Physiol. 2012, 227, 976–993.
[CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons by Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
